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When a patient who has just received a blood transfusion suddenly becomes short of breath 
to the point where it requires medical intervention, a diagnosis of transfusion-related acute 
lung injury (TRALI) should be considered. At present TRALI is thought to be the most 
frequent serious side effect of blood transfusions.1-4 However, the temporal relation to a 
transfusion is often overlooked and the fluid built-up in the lungs, visible in chest X-rays, is 
frequently blamed on cardiac problems. Furthermore, if kept on adequate supportive care, 
such as mechanical ventilation, most patients recover within four days.5-7 Therefore, TRALI 
can easily go unrecognized.8 This likely contributed to the fact that, for such a serious 
problem, it has only relatively recently started to receive much attention in the literature. 
Although TRALI was probably reported in the literature as early as the 1950s, those 
first reports were not specifically concerned with TRALI.9,10 The first report of what was 
likely a patient with TRALI was of a single case in a series of four cases all suffering from 
different transfusion related hypersensitivity reactions.9 The next publication that reported a 
likely TRALI case, mentioned this case only briefly while focusing more attention on the 
immunologic properties of leukocytes.10 Furthermore, this report actually concerned a 
patient who seems to have suffered primarily from an anaphylactic reaction with TRALI as 
a possible secondary reaction only.10 Both these publications likely concerned TRALI 
cases, but both lack the necessary information to be sure these cases would also be 
considered TRALI today and the authors certainly did not recognize TRALI as a distinct 
clinical entity.9,10 In 1962 the first TRALI case was published with sufficient clinical details 
to verify that it would meet today’s criteria.11 This publication, however, compared this 
case mainly with previous reports of febrile reactions and again did not recognize TRALI 
as a distinct syndrome.11 It wasn’t in fact until the second half of the 1960s that the 
literature started showing evidence that TRALI was first recognized as a distinct clinical 
entity.12,13 Subsequently the clinical syndrome that we now call TRALI was given a variety 
of names in case reports and small case series throughout the 1970s and the early 1980s.14-22 
Two decades after it was first recognized as a distinct transfusion-related complication the 
syndrome finally received the name we still use today.23 
By that time it had already been suggested repeatedly that TRALI was caused by the 
passive infusion of leukoagglutinins.10,11,14-19,21,22 These leukoagglutinins included 
antibodies against human neutrophil antigens (HNA) and human leukocyte antigens (HLA) 
of both classes I and II. These antibodies are now considered the most important risk factor 
for TRALI and are most commonly collectively referred to as leukocyte antibodies.5,23-27 
These antibodies are most prevalent in parous women and transfusion recipients (i.e. allo-
exposed individuals).28-33 Which has lead these groups of donors to be considered 
potentially more likely to cause TRALI.34-38 In recognition of this fact and the increased 
risk of other complications associated with the transfusion of HLA antibodies, some local 
blood banks (e.g. Blood bank Leiden) excluded plasma from parous and transfused donors 
from use for transfusion or the suspension of platelets as early as the 1970s. However, in 
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the absence of a firm evidence base, this practice was abandoned later upon organizational 
fusions with other blood banks who did not previously take these measures. 
In 1985 the publication of a large case series marked an important milestone in TRALI 
research.5 This publication first suggested the acronym TRALI for transfusion-related acute 
lung injury, the name introduced two years earlier by the same authors.23 It also suggested a 
definition that has changed remarkably little since then. Further, the first and arguably still 
most accurate estimate of the incidence of TRALI was made by closely monitoring all 
transfusion recipients at the Mayo Clinics in Rochester over a two year period. Finally, both 
donors and patients were tested for leukocyte antibodies and these were found in 89% of 
cases. There was no formal control group to ascertain the normal prevalence of leukocyte 
antibodies in the source population of donors and patients. Furthermore, most patients 
received transfusions from two or three donors, increasing the probability that at least one 
would test positive for leukocyte antibodies by chance alone. However, the authors clearly 
considered the observed number of positive cases to be higher than expected and concluded 
that leukocyte antibodies were an important risk factor for TRALI and this concept has 
dominated the TRALI literature ever since.5,23-27 
The definition proposed in 1985 was largely confirmed by the Canadian consensus 
conference nearly two decades later.39,40 The definition adopted by the conference and the 
European haemovigilance network (EHN) is based on the 1994 American-European 
consensus conference definition of acute respiratory distress syndrome (ARDS) and acute 
lung injury (ALI).40,41 Next to the usual requirements for ALI (i.e. acute respiratory distress, 
with bilateral infiltrates in the chest X-rays, in the absence of circulatory overload) the 
definition of TRALI also states the first symptoms have to occur within six hours of the last 
transfusion. This differs only minimally from the 1985 definition which required a 
maximum of four hours since the last transfusion.5 The chosen period of six hours is to 
some extend arbitrary and the rest of the definition held little surprises either. The main 
purpose of the consensus definition, however, was not to develop an entirely new 
definition. The consensus rather establishes a single, unambiguous definition to facilitate 
international research and communication. The biggest contribution of the consensus 
conference was probably the addition of the category of “possible TRALI” for patients who 
do meet the definition of TRALI but who also have other risk factors for ALI or ARDS.39,40 
This category was necessary since TRALI is clinically indistinguishable from ALI or 
ARDS caused independent of transfusions. Even the pathophysiology of TRALI is almost 
identical to that of ARDS, with activated neutrophils damaging the pulmonary vasculature. 
Only the cause of neutrophil activation is different, making the marked difference in 
prognosis rather surprising. Mortality of TRALI is estimated to be between five and ten 
percent and the majority of patients recovers spontaneously and completely within 96 
hours, on supportive care alone.5-7 
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With most of the research attention focused on leukocyte antibodies it took until 1997 
before a serious alternative cause for TRALI was first suggested in the form of biological 
response modifiers (BRM).42 These BRM can include biologically active lipids, peptides 
and any other substance, including antibodies, that can activate neutrophils.42-44 This new 
theory finally made it possible to explain TRALI occurring when neither donor nor 
recipient had detectable leukocyte antibodies. However, in spite of this new theory, 
leukocyte antibodies and donors who have a high prevalence of them have remained the 
prime focus of the TRALI literature. 
In their 2004 annual report the Serious Hazards Of Transfusion (SHOT; the 
haemovigilance organization of the United Kingdom) noted TRALI had become the leading 
cause of transfusion related serious morbidity and mortality in the United Kingdom. 
Therefore, they proposed to implement measures for the prevention of TRALI.45 Though 
there was still no numerical evidence of a relation between TRALI and leukocyte 
antibodies, much less any indication of the strength of such a relation, the SHOT advised 
the exclusion of plasma from female donors from use for transfusion whenever possible.45 
This advice included the use of plasma from female donors for the suspension of platelets 
for transfusion. Both plasma and the plasma used for the suspension of platelets in the 
United Kingdom are now derived from male donors in over 95% of products. 
Unfortunately, the SHOT uses serological findings to score the imputability of reported 
TRALI cases and most analyses are restricted to the highest levels of imputability only.45 
Therefore, serological findings at least partly determine inclusion of a TRALI case in the 
analyses precluding any conclusions regarding the role of antibodies to be drawn from their 
data. Further, since they rely on passive reporting and TRALI is believed to be severely 
underreported, the number of reported TRALI cases is a poor indicator of the real number 
of TRALI cases. The effect of preventive measures on the occurrence of TRALI in the 
United Kingdom is therefore impossible to judge. 
The TRALI literature until recently consisted almost exclusively of case series and 
case reports. Often investigations of leukocyte antibodies did not include all involved 
donors. A control group, to asses the normal prevalence of these antibodies in the source 
population, was never included. Further difficulties in using the literature to assess the role 
of leukocyte antibodies in the occurrence of TRALI arise from changes in blood products 
over time. For instance, the observation that six percent of TRALI is caused by leukocyte 
antibodies of the recipient reacting with transfused neutrophils5 has obviously become 
irrelevant in the age of universal leukoreduction. Finally, publication bias likely favored 
publication of serologically positive cases, causing a false or falsely increased association 
in the literature. These factors all contribute to the fact that evidence from the literature, for 
a relation between leukocyte antibodies and TRALI, was until December 2007 largely 
impossible to asses and indirect at best (as shown in Chapter 2). 
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Other methodological issues, remaining largely unrecognized in the entire transfusion 
literature, include the problems of confounding by indication (Chapter 3) and the presence 
of innocent bystander transfusions, causing effect estimate dilution (Chapter 4). The 
problem of effect estimate dilution caused by multiple transfusions is not easily solved by 
conventional statistical methods, but several different specialized solutions are possible. In 
Chapter 4 we use simulation studies to demonstrate the surprisingly strong effect dilution, 
the complete inadequacy of conventional correction methods in this setting, and the validity 
of four newly proposed solutions to this problem. 
In spite of the lack of numerical evidence and based primarily on the precautionary 
principle Sanquin (the Dutch blood supply foundation) has decided that all plasma 
donations intended for transfusion will be from never transfused male donors as of 1st 
October 2006. To lend scientific support to such preventive measures, we aimed to quantify 
the contribution of leukocyte antibodies, female donors, and allo-exposed donors to the 
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The majority of cases of transfusion-related acute lung injury (TRALI) are thought to be 
caused by the presence of leukocyte antibodies in the blood of the donor. We performed a 
systematic search of the literature to quantify the contribution of donor antibodies to the 
occurrence of TRALI. 
 
Study design and methods 
We conducted a systematic search of the PubMed and EMBASE databases. Retrieved 
articles were judged by three authors independently. Reference lists of all articles were 
subsequently screened for relevant references. All articles in English, German, French and 
Dutch, published at any time before December 2007 were eligible for inclusion. 
 
Results 
Of 77 articles, on leukocyte antibodies in donors involved in a case of TRALI, 14 articles 
contained sufficient data. These 14 articles reported leukocyte antibodies in 24 of 51 donors 
(47%) associated with 24 of 28 TRALI cases (86%). Of 15 articles that reported the 
prevalence of leukocyte antibodies in the general donor population, 2 articles reported a 
prevalence of 17% in (452) randomly selected donors. The odds ratio for developing 
TRALI was 15 (95% CI 5.1 to 45) for patients who received a transfusion from a donor 
who tested positive for leukocyte antibodies, compared to donors who tested negative. 
Leukocyte antibodies contributed to 80% (95% CI 51% to 92%) of all TRALI cases. 
 
Conclusion 
Leukocyte antibodies were more prevalent in donors involved in TRALI cases than among 
randomly selected donors. These findings suggest that donor antibodies contribute to four 
fifths of all TRALI cases. 
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Transfusion-related acute lung injury (TRALI) is clinically indistinguishable from acute 
respiratory distress syndrome (ARDS) and develops during, or shortly after, transfusion of 
one or more blood products.1 TRALI is currently recognized as the most common, severe 
side effect of blood components transfused.2-5 It has an estimated incidence of 1 in 5000 
transfusions and a mortality of 6%.1 It is thought to often be caused by donor derived 
leukocyte antibodies, which can be directed either against the human leukocyte antigens 
(HLA) or against the human neutrophil antigens (HNA). These antibodies could activate 
the recipient’s pulmonary neutrophils, which in turn damage the pulmonary endothelium. 
This causes pulmonary edema.1,6,7 
Since these antibodies are most frequently found in parous women and are present 
primarily in plasma rich blood products,8,9 it has been proposed to exclude parous women 
from donating plasma for transfusion.10 In many countries, among others the United 
Kingdom and the Netherlands, plasma from female donors is no longer used for 
transfusion, when possible.3 Although the situation does call for preliminary caution, other 
etiologies have also been suggested for TRALI.11-15 
The importance of other potential causes and the contribution of leukocyte antibodies 
to the occurrence of TRALI is unclear. Therefore, it is not possible to estimate the benefits, 
expected to be gained, by measures directed at the elimination of products containing these 
antibodies from the blood supply. 
Leukocyte antibodies do not always cause TRALI which is in part due to the 
heterogeneity of the HLA system. The presence of leukocyte antibodies in blood products 
is not particularly uncommon either,88,9 which raises the possibility that their presence is 
merely a chance finding in some TRALI cases. 
Therefore, to estimate the contribution of leukocyte antibodies to the occurrence of 
TRALI, the prevalence of these antibodies in a control group of randomly selected donors 
is needed, in addition to the prevalence in donors associated with a TRALI case. 
Unfortunately, this control group is generally not included in the TRALI literature, which 
consists mainly of case reports and case series. 
Furthermore, evidence from the literature might be biased by circular reasoning and 
publication bias, causing only those cases where leukocyte antibodies were identified to be 
diagnosed and published as TRALI cases. Given that leukocyte antibodies are present by 
coincidence in a certain portion of TRALI cases, publication bias would ensure an 
overestimated association of these antibodies with TRALI cases. 
To quantify the contribution of donor antibodies to the occurrence of TRALI, we 
compared the reported prevalence of leukocyte antibodies, in donors associated with cases 





We performed a literature based study into the role of donor leukocyte antibodies in 
TRALI. Case reports and case series from the literature were included to obtain data on 
antibody prevalence in donors associated with TRALI cases. These data were compared to 
a control group provided by reports on the prevalence of leukocyte antibodies in the donor 
population in general. Leukocyte antibody prevalences in these two groups were compared 
as described below in more detail. 
To correct for differences between patients in the number of received transfusions, all 
prevalences determined in donors were recalculated to the number of patients that could 
potentially be transfused with antibody containing components, assuming all patients 
received the same number of transfusions. From this comparison we obtained the odds 
ratio, as an estimate of the relative risk for TRALI associated with the presence of 
leukocyte antibodies in transfused blood product. 
Our question concerns the role of leukocyte antibodies in general and does not 
distinguish the relative contribution of anti-HNA or anti-HLA antibodies, nor does it focus 
on the role of antibodies that match with cognate antigens in the recipient. The available 
literature does not allow these additional comparisons to be made. 
We performed an automated search of the literature and subsequently used 
predetermined criteria to include or exclude articles retrieved by this literature search. 
These criteria were chosen to select articles that would provide all data necessary for our 
comparison in the least biased way possible. 
 
Search strategies 
We conducted a systematic search of the PubMed and EMBASE databases, searching for 
articles mentioning either “lung” or “pulmonary” in combination with either “injury” or 
“edema” and mentioning “blood transfusion” while also mentioning either “antibodies” or 
“antigens” in any way. The complete search strategy is given in Appendix I. The resulting 
list of titles was judged for relevance by three authors independently and, of these selected 
articles, the abstracts were judged similarly. Exclusion criteria were: review (non-original 
data), animal study, in vitro study, stem cell transplantation or “different topic”. The 
reference lists of all articles, that were thus selected, were subsequently screened for 
relevant references, which had not been retrieved by the search. 
An automatic search of the PubMed and EMBASE databases, for articles containing 
information on the prevalence of leukocyte antibodies in the general population, returned 
no articles with relevant information (see Appendix I for search strategy). Therefore, 
articles on this subject were selected solely from the reference lists of the articles selected 
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from the TRALI literature. Subsequently, we continued checking reference lists of referred 
articles until no relevant new references were found. 
A flowchart of the selection process is presented in Figure 1. All articles in English, 
German, French and Dutch, published before December 2007 were eligible for inclusion. 
 
Definitions 
Articles that reported on measuring leukocyte antibodies in donors involved in TRALI 
cases (TRALI donors) were judged, in several steps, for the type of data available and the 
definition of TRALI used. A flowchart of the exclusion process is presented in Figure 2. 
In each of these steps articles were excluded if they did not contain the information 
required for our analyses. In the successive exclusion steps, articles were excluded if they 
failed to report the number of TRALI cases tested, the number of donors tested, or the 
definition of TRALI used. Furthermore, articles were excluded if the presence of leukocyte 
antibodies was included in the definition of TRALI, the definition did not correspond to the 
clinical definition of TRALI that was agreed upon at the Canadian consensus conference in 
Toronto,16,17 or if not all involved donors were tested. 
In each successive step we documented the number of articles excluded during this 
step. For the remaining articles we assessed the number of TRALI cases reported, the 
number and percentage of TRALI cases with at least one donor tested positive for 
leukocyte antibodies, the number of donors tested, and the number and percentage of 
donors tested positive for leukocyte antibodies (Figure 2). 
Articles that reported on the prevalence of leukocyte antibodies in the general 
population were included if the study population consisted of randomly selected donors. All 
articles reporting on specific subpopulations, such as female donors, (multi-)parous donors 
or previously transfused donors were excluded. 
 
Analyses 
The weighted average of the reported prevalences of leukocyte antibodies, among randomly 
selected donors, was calculated. This prevalence was used to estimate the number of donors 
with leukocyte antibodies that would be expected among donors not involved in TRALI 
cases. This expectation was corrected for the number of components transfused (Table 1, 
row 2), which was set as equal to that of the TRALI cases. The resulting expected number 
was subsequently compared to the observed number of donors with leukocyte antibodies 
among the donors that were involved in TRALI cases (Table 1, row 1). 
Furthermore, the odds ratio (OR), and corresponding 95% confidence interval (CI), 
were calculated. The calculated OR was the ratio of the odds for developing a TRALI after 
being transfused with at least one product containing leukocyte antibodies, compared to the 
odds of developing a TRALI after being transfused only with products not containing 
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leukocyte antibodies, given that patients in both situations had an equal number of 
components transfused. This odds ratio is an estimation of the relative risk of developing a 
TRALI after being transfused with at least one product containing leukocyte antibodies, 
compared to the risk of developing a TRALI after being transfused as many products 
without leukocyte antibodies. 
Finally, given the assumption that an observed association between leukocyte 
antibodies and TRALI was causal, the excess presence of antibodies could be used to 
calculate the fraction of TRALI cases explained by these antibodies. This was done by 
calculating the population attributable risk (PAR), i.e. the percentage of all TRALI cases 
that could be attributed to the presence of leukocyte antibodies, and the corresponding 95% 
CI. The OR and its variance were entered into the appropriate formulas to calculate the 




A total of 82 articles contained information on the prevalence of leukocyte antibodies in 
donors who had donated blood that was transfused to TRALI patients. A further 15 articles 
contained information on the prevalence of these antibodies in either the general population 
or a donor population. Figure 1 shows a flowchart of the selection process of these 97 
articles. The complete lists of references for both searches are given in Appendix II. 
 
Leukocyte antibodies and TRALI 
Of 82 articles, eight were excluded because they failed to state the number of cases in 
which one or more donors tested positive for leukocyte antibodies. The 74 remaining 
articles showed 75% of 258 cases to involve at least one donor that tested positive. A total 
of 57 articles reported both the number of donors tested and the number of donors tested 
positive. From these the prevalence among 364 donors involved in 122 TRALI cases was 
estimated to be 32%. As shown in Figure 2, further stepwise exclusion of articles affected 
both these percentages. 
Only 14 articles met all criteria for containing necessary data, reporting an average 
prevalence of 47% (24 donors positive of 51 tested), resulting in 86% of 28 cases in which 
at least one donor was tested positive for leukocyte antibodies (Table 1). Of these 14 
articles eleven were case reports,19-29 two reported on two cases each,30,31 and one reported 
on 13 cases.32 The average leukocyte antibody prevalence among the 13 articles reporting 
on 2 cases or less was 42%, while the prevalence reported in the case series of 13 cases was 
62%. This corresponded to 93% and 77% of cases in which one or more donors tested 
positive for leukocyte antibodies, respectively. TRALI patients had an average of 1.8 
(51/28) blood components transfused. 
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Figure 1: Flowchart of selection of relevant articles from the literature search. Values are numbers of articles. The 
literature search for leukocyte antibodies in the general population returned 309 articles. These were not included 
in this chart, since none contained relevant information. Articles on this subject were, instead, selected from 
reference lists only (see text for details). 
 
 
Leukocyte antibodies in the donor population 
The literature search for leukocyte antibodies in the general population returned 309 
articles. None contained relevant information. Articles on this subject were, instead, 
selected from reference lists only. 
The prevalence of leukocyte antibodies in the general population or donor populations, 
as reported in the 15 articles included on this subject, ranged from 3% to 48%. Only two of 
these articles reported on 452 randomly drawn donors,33,34 therefore representing the male-
female-ratio found in those donor populations. The weighted average of the prevalence of 




Transfusion of 452 products to control patients, each receiving 1.8 transfusions, would 
have resulted in the transfusion of 248 patients. Of these 248 control patients 70 would 
have been transfused with at least one product from a donor with leukocyte antibodies 
(Table 1). 
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Figure 2: Flowchart of stepwise exclusion of 68 articles on TRALI donors in which insufficient information was 
reported. Values are numbers or percentages, as indicated below. The central column shows the number of articles 
decreasing stepwise from 82 to 14. *Articles/Cases: Numbers of articles and cases that were excluded in this step. 
†Case/Positive (%): Number of TRALI cases with information about the presence of leukocyte antibodies in one or 
more donors / Number of TRALI cases in which one or more  donors were tested positive for leukocyte antibodies 
(TRALI cases in which 1 donor tested positive as percentage of all TRALI cases in which 1 donor was tested). 
‡Donors/Positive (%): Number of donors tested / Number of donors tested positive (donors tested positive as 
percentage of total donors tested). C.C. definition: Canadian Consensus definition. 
 
 
Comparison of observed and expected prevalences 
The prevalence of leukocyte antibodies in donors involved in TRALI cases was higher than 
the prevalence in a group of randomly selected donors (47% versus 17%). Leukocyte 
antibodies were detected in 24 of 28 TRALI cases (86%). In each of these cases only one 
donor was tested positive, resulting in 24 of 51 donors (47%) testing positive. 
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The odds ratio for developing TRALI was 15 (95% CI 5.1 to 45) for patients who 
received a transfusion from at least one donor who tested positive for leukocyte antibodies, 
compared to patients who received an equal number of transfusions from donors who tested 
negative (Table 1). The population attributable risk was 80% (95% CI 51% to 92%). 
 
 Table 1: Number of TRALI cases and control patients with 
and without leukocyte antibodies present in at least one donor
  Leukocyte antibodies    
 TRALI + - Total OR* 95% CI 
 + 24  4  28    
 - 70† 178† 248† 15 5 to 48 
 Total 94  182  276    
*The OR has been calculated by the cross-product: (24*178)/ (4*70)=15  
†Number of control patients that would have been transfused (in each group) with
the 452 products from the randomly drawn donors, if each of them would have






Our systematic review of the literature shows that the prevalence of leukocyte antibodies in 
donors involved in reported TRALI cases was higher than the prevalence reported among 
randomly selected donors. Our findings suggest four fifths of all cases of TRALI are 
explained by the presence of antibodies in donors. 
Many articles on TRALI cases did not contain all the required information, or did not 
define TRALI according to the Canadian consensus definition.16,17 Furthermore, to avoid 
the pitfall of circular reasoning, we excluded all reports in which the diagnosis of TRALI 
was made with knowledge of the antibody status of associated donors. This left us with 
only a minority of the TRALI publications. Data from only 28 of a total of 498 reported 
TRALI cases could be included in this review. Although this represents only a limited 
fraction of the total literature data, it gives the least biased estimate, due to systematic 
selection based on objectively predetermined criteria. 
We could not include several large, well designed studies because they did not report 
on all data required for our analyses. One of these studies was the important publication by 
Popovsky and Moore in Transfusion, 1985.1 Since this one study alone included a similar 
number of cases as the combination of all studies included in this review, we contacted the 
authors. Although the individual, case-specific data are no longer available after 22 years, 
averages could still be obtained. In 89% of cases one or more donors tested positive for 
leukocyte antibodies. In two or three of these cases more than one donor tested positive and 
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two to three donors were tested per case (personal communication, Mark A. Popovsky, 
august 2007). This leads to an estimation of the leukocyte antibody prevalence of between 
32% and 49%, which is very similar to the results we obtained in our analyses. 
Our study does not take into account antibody specificity, since our primary aim is to 
quantify the risk imposed by antibodies in the blood supply. From the perspective of the 
blood bank the presence of cognate antigens is not relevant, since it can not be known 
beforehand whether a future recipient will have the cognate antigen. The chance of 
antibodies causing TRALI can therefore be viewed as composed of both the chance of a 
recipient expressing cognate antigens and the chance of a recipient with cognate antigens 
being sensitive to developing TRALI. We use the prevalence of leukocyte antibodies in 
randomly selected donors as a control group. Therefore the calculated contribution of these 
antibodies to the occurrence of TRALI reflects the excess presence of antibodies, above the 
expected value. This excess presence can be explained only by biological significance, 
statistical variation and bias. Statistical variation is controlled for in the calculation of the 
95% CI, which leaves only bias as an alternative to biological significance to explain our 
results. Possible causes of bias are further discussed below. 
A large part of the literature reporting on TRALI cases is comprised of reports of one 
or two cases only, while larger case series remain relatively rare. Of the 14 articles that 
were included in this study only one reported on more than two cases. This article reported 
a lower fraction of positive cases (77%) than that reported in the case reports (93%). This is 
suggestive of publication bias in favor of reports of cases in which at least one donor was 
tested positive for these antibodies. Such bias may have lead to overestimation of the 
contribution of antibodies to the occurrence of TRALI in this systematic analysis. 
Furthermore, it should be noted that other etiologies of TRALI have been suggested 
more recently35 and may have a less severe clinical presentation.7 Therefore, in these cases 
chest X-rays, which are required according to the Canadian consensus definition, may be 
performed less often. These studies would therefore be excludes from this review. Strict 
adherence to objectively predetermined criteria does result in the least biased estimate of 
the contribution of leukocyte antibodies to the occurrence of TRALI as defined according 
to the Canadian consensus definition.16,17 However, less severe TRALI, which could still be 
clinically relevant, might not meet all criteria of this definition. Therefore, an etiological 
difference between less severe and severe TRALI can not be excluded based on our results. 
The presented prevalence in the general donor population is based on only two studies, 
which could raise questions about the extrapolation of these results to other donor 
populations. Although there is not enough information to judge this in detail, one of these 
studies mentions 40% of the donors to be female. This does not seem a particularly 
unexpected percentage and thereby suggests the data from this study to be likely to apply to 
other donor populations as well. 
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The last possible source of bias is the presence of uncontrolled confounding. This 
would require there to be an unmeasured factor that is associated with the presence of 
leukocyte antibodies, but is causing TRALI by a mechanism unrelated to these antibodies. 
However, there seems no alternative biological mechanism readily identifiable that could 
convincingly explain the observed association of leukocyte antibodies with the occurrence 
of TRALI by means of confounding. 
From this review the best estimate of the risk associated with the transfusion of 
leukocyte antibody containing blood products is a 15-fold increase in the odds of TRALI, 
compared to the transfusion of products not containing these antibodies. Of all TRALI 
cases, analyzed in this review, 80% are estimated to be attributable to donor derived 
antibodies. However, since the studies included in this review were not designed to 
investigate this specific question results could still be biased for several reasons, including 
publication bias. Therefore, new studies specifically designed to quantify the contribution 
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Search strategy for TRALI and antibodies in PubMed 
(“transfusion associated acute lung injury”[tiab] OR “transfusion related acute lung 
injury”[tiab] OR TRALI OR “transfusion associated respiratory distress”[tiab] OR ("Blood 
Transfusion/adverse effects"[Mesh] AND "Respiratory Distress Syndrome, Adult"[Mesh]) 
OR (“acute lung injury”[ti] AND transfusion[ti]) OR (“pulmonary reaction*”[ti] AND 
transfusion[ti]) OR “pulmonary transfusion reaction*”[tiab] OR (“pulmonary injury”[ti] 
AND transfusion[ti]) OR (“pulmonary edema”[ti] AND transfusion[ti]) OR (“lung 
edema”[ti] AND transfusion[ti]) OR (“pulmonary oedema”[ti] AND transfusion[ti]) OR 
(“lung oedema”[ti] AND transfusion[ti])) AND (Alloantibodies OR alloantibody OR 
Alloantigens OR alloantigen OR "Isoantigens"[MeSH] OR isoantigens OR isoantigen OR 
"Isoantibodies"[MeSH] OR isoantibodies OR isoantibody OR Alloantibod*[tiab] OR 
Alloantigen*[tiab] OR Isoantibod*[tiab] OR Isoantigen*[tiab] OR "Antibodies"[MeSH] 
OR antibody OR antibodies) 
 
Search strategy for TRALI and antibodies in EMBASE 
(((transfusion associated acute lung injury OR transfusion related acute lung injury OR 
TRALI OR transfusion-associated respiratory distress OR (acute lung injury AND 
transfus$)).ti,ab) OR exp Transfusion Related Acute Lung Injury/ OR (Acute lung injury/ 
AND exp Blood transfusion/) OR (exp Adult Respiratory Distress Syndrome/ AND exp 
Blood Transfusion/) OR (pulmonary reaction$.ti AND transfusion.ti) OR pulmonary 
transfusion reaction$.ti,ab OR (pulmonary injury.ti AND transfusion.ti) OR (pulmonary 
edema$.ti AND transfusion.ti) OR (lung edema$.ti AND transfusion.ti) OR (pulmonary 
oedema$.ti AND transfusion.ti) OR (lung oedema$.ti AND transfusion.ti)) AND 
((alloantibod$ OR alloantigen$ OR isoantigen$ OR isoantigen OR isoantibod$ OR 
antibod$).ti,ab OR exp Antibody/ OR exp Alloantigen/) 
 
Search strategy for prevalence of antileukocyte antibodies in PubMed 
(Alloantibodies OR alloantibody OR Alloantigens OR alloantigen OR 
"Isoantigens"[MeSH] OR isoantigens OR isoantigen OR "Isoantibodies"[MeSH] OR 
isoantibodies OR isoantibody OR Alloantibod*[tiab] OR Alloantigen*[tiab] OR 
Isoantibod*[tiab] OR Isoantigen*[tiab] OR "Antibodies"[MeSH] OR antibody OR 
antibodies) AND ("anti-hla" OR "anti-hna" OR “anti-leukocyte” OR “anti-granulocyte” OR 
“anti-neutrophil”) AND ("Epidemiology"[MeSH] OR "Prevalence"[MeSH] OR 
"Incidence"[MeSH] OR prevalence [tiab] OR incidence [tiab]) 
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Search strategy for prevalence of antileukocyte antibodies in EMBASE 
((alloantibod$ OR alloantigen$ OR isoantigen$ OR isoantigen OR isoantibod$ OR 
antibod$).ti,ab OR exp Antibody/ OR exp Alloantigen/) AND (anti-hla OR anti-hna OR 
anti-leukocyte OR anti-granulocyte OR anti-neutrophil) AND (exp epidemiology/ OR 
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Introduction 
Confounding by indication is a serious potential problem in clinical observational research 
and can easily lead to unjustified conclusions, as has also been described previously.1 In 
transfusion medicine such a conclusion could be “blood transfusions kill”, since patients 
receiving more transfusions are almost invariably more likely to die. Even though most 
would agree that blood transfusions save lives, this erroneous conclusion did find its way 
into the literature. Though this example might seem overly obvious, confounding by 
indication can be indirect and much more subtle and hard to detect. It is therefore of the 
utmost importance to thoroughly understand the nature of confounding by indication, to be 
able to recognize it and avoid unjustified conclusions. We introduce the problem of 
confounding by indication with examples from clinical transfusion research and provide a 
general explanation to help identify this form of bias in the literature and in the every day 




 Table 1: Guidelines on detection and handling of confounding by indication  
 1  Clearly define the outcome under study and identify known risk factors for 
this outcome 
 
 2  Define what aspect of transfusions is being investigated as a potential 
cause of this outcome (i.e. what is the exposure of interest) 
 
 3  Verify whether the exposure (step 2) depends on other transfusion 
parameters (e.g. male-only plasma recipients are less likely after more 
transfusions; the number of transfusions being the “other parameter” and 
male-only being the exposure) 
 
 4  Consider whether the exposure (step 2) or any of the other transfusion 
parameters (step 3) are related to risk factors for the outcome (step 1) 
 
 5 A When designing a study: consider restricting the study to patients with 
identical risk factors for the outcome or gathering additional information 
on these risk factors, to allow for correction* 
  B When reading a published study: check whether the authors performed all 
of the above steps. If not, did they supply the necessary information for 
you to be convinced that confounding by indication is not a problem in 
their study? 
 * Note: correction for confounding by indication is notoriously difficult, since patients get treated 
based on the risks perceived by the clinician and it is virtually impossible to capture all of the 
clinician’s considerations in a statistical model. Furthermore, multiple transfusions can also give 
other types of bias, which can not always be corrected by conventional methods.4
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Confounding by indication 
Confounding by indication is a bias in clinical observational research that disturbs the 
association between a treatment and an outcome.1-3 This bias occurs when studying the 
effect of a treatment, while the indication for the treatment causes the outcome. Patients 
with the indication are more likely both to receive the treatment and to experience the 
outcome, even if the treatment is not actually causing the outcome. This form of bias is 
called confounding by indication, since the association between the treatment and the 
outcome is confounded by the indication for the treatment. Sometimes this is also referred 
to as selection bias because the bias is caused by patients being selected for treatment. 
However, since the term selection bias is also commonly used to denote a multitude of 
other sources of bias, we prefer to call this type of bias confounding by indication. 
Confounding by indication can be avoided by performing a randomized clinical trial 
(RCT).2 In an RCT the allocation of treatment is independent of factors capable of causing 
the outcome (i.e. independent of indication). Many questions, however, can not be studied 
in an RCT, since this would be unethical or practically impossible. Therefore, much clinical 
research is observational and subject to the bias of confounding by indication. Unless 
adequately corrected for in the analyses, this bias prohibits any association between 
treatment and outcome from being interpreted as representing a causal relationship. 
Therefore, it is of the utmost importance to recognize and prevent or correct for 
confounding by indication. 
 
Confounding by indication in transfusion medicine 
In transfusion medicine the most common form of confounding by indication involves the 
number of transfusions received by a patient. Clearly, the sicker a patient is, the more 
transfusions will be indicated. Also, the sicker a patients is, the higher the risk that patient 
will have a poor outcome. Figure 1 illustrates how this causes a spurious association 
between receiving a high number of transfusions and experiencing a poor outcome, an 
association which should obviously not be interpreted as causal. 
 
Indirect confounding by indication 
A less easily recognized problem is “indirect confounding by indication”. In this case the 
indication still causes the outcome, but the relation with the treatment is indirect. If we 
again consider the example of a sicker patient receiving more transfusions, we can see that 
any other difference in treatment secondary to this higher number of transfusions will also 
become associated with poor outcome. For example we can imagine that patients receiving 
more transfusions are less likely to receive all transfusions from male donors (figure 2 A). 
Thus, comparing male-only to mixed-sex plasma transfusions will show a benefit for male-
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only plasma where none exists. Importantly, the comparison of female-only to mixed-sex 
plasma transfusions should show a similar spurious association. An analogous situation 
with opposite bias arises for an analysis of the oldest unit transfused, which will on average 
be older in patients receiving more transfusions. A similar effect can be shown in the data 




More transfusions Poor outcome  
 
Figure 1: Cartoon of direct confounding by indication. Arrows indicate causal relationships and the dashed line 
denotes a spurious association. A more seriously ill patient is likely to receive more transfusions and experience a 
poor outcome. Therefore, a spurious association between receiving many transfusions and experiencing a poor 
outcome is created. This association is spurious because it is confounded by the indication for more transfusions 
(i.e. being more seriously ill). If in this example we were interested in the relation between the number of 
transfusions and a poor outcome (e.g. mortality) it would seem like transfusions are causing mortality, while this 













Figure 2: Cartoons of indirect confounding by indication. Arrows indicate causal relationships and the dashed 
lines denote spurious associations. A: If transfusions are allocated independent of donor sex, receiving more 
transfusions will reduce the probability of receiving all transfusions from male donors. Since the number of 
transfusions was (spuriously) positively associated with poor outcome (see figure 1), receiving all transfusions 
from male donors will become (spuriously) negatively associated with poor outcome. If in this example we were 
interested in the relation between donor sex and a negative outcome (e.g. TRALI) it would seem like receiving 
transfusions only from male donors is protecting against TRALI (and therefore like female donors are causing 
TRALI), while this association is actually not causal. B: If clinicians believe younger blood to be safer and 
therefore specifically reserve or order younger blood for more vulnerable patients with poorer prognosis, a 
(spurious) negative association between high product age and poor outcome will be created. If in this example we 
were interested in the relation between storage time and a negative outcome (e.g. mortality) it would seem like 
receiving younger blood causes mortality, while this association is actually not causal but created by the clinician. 
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Correction for confounding by indication 
The association between receiving all transfusions from male or female donors and the 
number of transfusions is based on probability distributions, as is the association of the age 
of the oldest or youngest unit and the number of transfusions. Therefore, the strength of this 
association can be predicted based on the number of transfusions and a correction can then 
be applied. It should be noted however that a simple correction for the number of 
transfusions does not usually suffice.4 Although the adequate correction is therefore not 
always straightforward to apply in practice, it does result in an unbiased estimate of the 
causal effect of donor sex or product age. 
 
When no correction is possible 
A problem that is generally beyond any hope of repair arises in the case where clinicians 
specifically ask for younger blood for their most vulnerable patients (figure 2 B). Young 
blood will then become spuriously associated with poor outcome and the strength of this 
spurious association can not be determined in any way. A similar problem, resulting in an 
association in the opposite direction, arises when blood banks specifically issue their oldest 
units for expected heavy bleeders. The blood bank only aims to reduce the chance of old 
units being returned to the blood bank near their expiration date, but it also ascertains that 
heavy bleeders who presumably have a poor prognosis get older blood. In both these 
examples the strength of the spurious association is not readily determined and correction is 
therefore not possible. 
 
Implications 
For an overview of a few simple steps that will help identify and deal with confounding by 
indication, see Table 1. Obviously, real causal relationships can be present alongside 
confounding by indication. However, these can not be quantified, or even qualitatively 
proven, and might in fact be completely obscured or even reversed, unless the bias of 
spurious associations is adequately corrected. It is therefore important to always realize 
which patient characteristics can both influence prognosis and are associated (directly or 
indirectly) with the treatment, or the secondary characteristics of treatment. Not all 
confounding by indication can be completely corrected for and adequate correction might 
require additional information. Therefore, it is vital to consider all these issues in the design 
phase of any study, when patient selection and data collection can still be adapted to avoid 
confounding by indication or allow for correction. 
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A problem when studying adverse events of blood transfusions is that patients have usually 
received transfusions from several donors while only one of these donors is the actual 
cause. This will result in underestimation of the effect of donor related risk factors if not 
adequately corrected for. We encountered this problem when studying transfusion-related 
acute lung injury (TRALI) and describe four methods to overcome this problem. 
 
Study design and methods 
Simulated data are used to illustrate the results of six different approaches: not correcting 
for the number of donors, using standard correction methods, and four newly proposed 
methods. Donor sex is used throughout as an example. The first two new methods apply 
restriction of the study to cases who have received a transfusion from a single donor or 
from donors who are all of the same sex. In both restriction designs the sex of the causal 
donors is known and can be compared to the expected value from a reference population. 
The other two new methods apply statistical correction for the number of donors, either by 
standardization or by maximum likelihood methods. 
 
Results 
If not corrected for, or if corrected for by standard methods, increasing numbers of donors 
per patient result in decreasing estimates of the effect of risk factors. All four newly 
proposed methods yield valid estimates. 
 
Conclusion 
It is clear that the problem of multiple transfusions requires specialized correction methods. 








Many adverse events associated with blood transfusions are due to one single transfusion, 
like transfusion transmitted infections, allo-immunization, most anaphylactic and allergic 
reactions, and transfusion-related acute lung injury (TRALI). The majority of transfusion 
recipients receive more than one transfusion. In most cases of adverse events it is not 
possible to identify the single causal transfusion. This complicates many studies that 
examine the association between donor related risk factors and transfusion reactions. We 
encountered this problem when studying TRALI. 
TRALI is a form of acute respiratory distress syndrome (ARDS) that develops during, 
or within six hours after, the transfusion of one or more blood products.1 TRALI is 
currently recognized as the most common of the severe side effects of blood transfusion.2-5 
It has an estimated incidence of 1 in 5,000 transfusions and a mortality commonly 
estimated to be between 5 and 10%, with the majority of patients spontaneously recovering 
within 96 hours, without long term sequelae.1,6,7 
Both patient and donor related risk factors are thought to be involved in TRALI. Of 
the donor related risk factors, donor derived leukocyte antibodies are thought to be the most 
important.1,8,9 Leukocyte antibodies are almost exclusively found in donors who have 
previously been exposed to allo-antigens and the large majority of allo-exposed donors are 
women who have been pregnant.10,11 Therefore, donor sex is considered an important donor 
related risk factor for TRALI and several countries have excluded female donors from 
donation of plasma for transfusion. Since it is so important and can be determined so easily, 
donor sex will be used as an example throughout this paper. 
Obtaining a quantitative estimate of the contribution of female donors to the 
occurrence of TRALI is complicated by the fact that in most cases TRALI patients have 
received transfusions from more than one donor before developing TRALI. Figure 1 gives a 
histogram of the number of donors involved in each case of a Dutch case series of 86 
TRALI patients. In this representative case series 85% of TRALI patients have received 
transfusions of more than one donor in the six hours before the onset of symptoms. All 
donors of blood products transfused in this six hour window have to be considered as 
potentially causal. However, due to the low incidence of TRALI it can be assumed that the 
probability of having two causal transfusions is negligibly small. It is generally accepted 
that TRALI is caused by a transfusion from only one of the donors, the causal donor. 
Consequently, without identification of this causal donor, the crude quantitative estimate of 
the contribution of female donors to the occurrence of TRALI will be an underestimation. 
The dilution effect resulting from transfusions from multiple donors can be quite 
substantial and conventional methods to correct for the number of transfusions (like 
stratifying by the number of transfusions or adding the number of transfusions in a 
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regression model) do not result in adequate correction. We discuss four approaches to 
obtain valid estimates of the contribution of female donors to the occurrence of TRALI. We 
simulated 1,000 data sets, each comprising 1,000,000 transfusion recipients, to describe the 
dilution effect of multiple transfusions, to illustrate the inadequacy of standard correction 
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Figure 1: The number of donors involved in a series of 86 Dutch TRALI patients. 
 
 
Materials and Methods 
 
We will present here an informal description of the comparisons made between donors 
associated with TRALI cases and the source population of these donors. For a mathematical 
presentation of these comparisons we refer the interested reader to the Appendix. In the text 
we will also present simple numerical examples with each method. For the first three 
methods the actual calculations can be demonstrated in these examples; the last method 
(Correction by maximum likelihood estimation) requires specialized software to maximize 
the likelihood formula and the actual calculations can therefore not be presented. 
Thereafter, we will present the large sample simulations. 
 
Adverse events and multiple transfusions 
53 
Assumptions and definitions 
 
Two types of TRALI patients 
We assume that TRALI can be caused by a women specific mechanism (i.e. antibodies as a 
consequence of pregnancies) or by unspecified other mechanisms (i.e. either antibodies due 
to other types of immunizing events, or other causes all together). Thus some TRALI cases 
are caused by female donors and could have been prevented by the exclusion of female 
donors. Such cases are caused by a women specific mechanism and will be referred to as 
“type I TRALI” cases. All other TRALI cases will be referred to as “type II TRALI”. 
Amongst the type II TRALI cases there are also TRALI patients who have received blood 
from one or more female donors. However, in these cases the sex of the donor was a 
coincidence, rather than a causal prerequisite (i.e. either none of the female donors was 
causal, or one of the female donors was causal, but not due to a women specific 
mechanism). These type II TRALI cases were, therefore, caused independent of donor sex. 
 
Problem of multiple donors 
In standard etiological studies the exposure prevalence among cases is compared with that 
of the source population of the cases in a twofold table (table 1). All figures in table 1 
represent numbers of patients, either with or without disease and with or without exposure 
to a female donor. If a TRALI patient (in the table referred to as TRALI +) received blood 
from only one donor and that donor was female, the patient is considered a female exposed 
case (A) and if the only donor was male the patient will be considered a female unexposed 
case (B). However, if the TRALI patient received more than one transfusion the causal 
transfusion is not known. Therefore, the values for cells A and B are not known and table 1 
can not be composed directly. The four methods we propose describe different methods of 
dealing with this problem. 
 
 Table 1: Patients with TRALI, who have received 
transfusions from a single donor (TRALI +) and reference 
patients who also received a transfusion (TRALI -) according 
to the sex of one donor 
 
 TRALI Female donor Male donor Total  
 + A B N1  
 - C D N2  
 Total M1 M2 T  




Data assumed available or computable 
We assume that for each TRALI patient with multiple donors we know the numbers of 
female and male donors. These observed numbers of female and male donors will need to 
be compared with expected numbers of female and male donors. The expected numbers can 
be estimated from the number of transfusions received and the fractions of female and male 
donations, as can be documented from the relevant donor population. Relevant in this 
context means: the donor population that represents the expected sex distribution for the 
donors involved in the TRALI case. The sex distribution of donors can be different between 
different countries or regions and between different product types and can also change over 
time. Therefore, the relevant donor population will, in practice, be a donor population 
donating the product type received by the TRALI patient, in the same geographical area, 
and during the same period as the TRALI occurred. 
 
Definition of measure of effect 
Our aim is to estimate the population attributable risk (PAR, the fraction of type I TRALI) 
as a measure of the contribution of female donors to the occurrence of TRALI. Estimation 
of the population attributable risk in the first two methods (restriction based methods) 
requires the relative risk (RR) to be estimated first. In the last two methods (correction 
based methods) the population attributable risk is estimated directly and the RR is 




1. Restriction to single donor cases 
The first and simplest method to remove the diluting effect of multiple donors is to restrict 
the study to TRALI cases who have received transfusions from only one donor in the six 
hour period preceding the onset of symptoms. Since this one donor is by definition the 
causal one, the sex of this donor can be compared directly with the expected fraction of 
female donors. The expected value equals the fraction of blood products donated by female 
donors in the reference population. If the majority of TRALI cases would be caused by 
unspecified mechanisms (i.e. non-women specific mechanisms), the fraction of female 
donors among cases will be similar to that in the reference population and the relative risk 
(RR) will be close to unity. 
Since the problem of multiple transfusions is effectively removed from the data, the 
population attributable risk can be calculated using standard formulas (Appendix, equations 
1 and 2). The standard error and confidence interval for the estimated population 
attributable risk can be calculated using the delta method.12 
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For example, if the fraction of blood products donated by female donors is 0.35 and 20 
patients have each received only a single transfusion before developing TRALI, 8 of which 
were from female donors. The RR would be 1.2 (i.e. [8x0.65]/[12x0.35]) and the population 
attributable risk would consequently be 8% (i.e. [0.35x1.2-0.35]/[0.35x1.2+0.65]). 
 
2. Restriction to unisex cases 
The second method also involves restriction of the study population to selected TRALI 
cases. In this case TRALI patients who have received transfusions either only from male 
donors or only from female donors (unisex cases) are included and compared to the 
reference population. If all donors involved in a TRALI case are of the same sex, this sex 
must be the sex of the causal donor. Therefore, the sex of the causal donor is known, even if 
the causal donor is not explicitly identified. 
Since the sex of the causal donor is known, the relative risk of TRALI for a transfusion 
from a female donor versus a male donor can be calculated. However, the probabilities of 
receiving all transfusions either only from male donors or only from female donors are not 
necessarily equal to the fractions of donations made by female and male donors. Instead we 
should determine the relative probabilities of receiving multiple transfusions from only 
female and only male donors, given that we already know this TRALI patient to be a unisex 
case. These probabilities can easily be calculated if we know the number of transfusions 
received and the fractions of donations made by female and male donors (Appendix, 
equations 3 and 4). Further calculations of the RR and population attributable risk are 
identical to those used after restriction to single donor cases. 
Consider the next example; if the fraction of blood products donated by female donors 
is again 0.35 and 20 patients have each received three transfusions, either only from male 
donors or only from female donors, before developing TRALI. Of these 20 patients 8 
received all three transfusions from female donors. Since we have selected unisex cases we 
have to compare the number of cases caused by female and male donors to the number of 
unisex transfusion recipients, without TRALI, who received the same number of 
transfusions from female and male donors (Appendix, equations 3 and 4). Out of 20 unisex 
recipients receiving three transfusions each we would expect 2.7 to have received all three 
transfusions from female donors (i.e. 0.353/[0.353+0.653]). The RR would be 4.3 (i.e. 
[8x17.3]/[12x2.7]) and the population attributable risk would consequently be 31% (i.e. 
[2.7x4.3-2.7]/[2.7x4.3+17.3]). 
 
3. Correction by standardization 
The third method applies direct standardization, according to the exposure in the reference 
population, to correct for the number of transfusions received by each TRALI patient. It 
consists of three steps. First, we estimate the total number of TRALI patients for whom the 
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causal transfusion was from a female donor (Appendix, equation 5). This number 
comprises all patients with a type I TRALI, i.e. those in which case the causal transfusion 
by definition has to be from a female donor, and a number of type II TRALI cases, i.e. in 
whom the causal transfusion is from a female donor by chance. 
Second, from the fractions of female donors in the different reference populations 
(which can be different for each TRALI patient), we calculate a weighted average 
(Appendix, equation 6). This is the fraction of cases that is expected to be exposed. 
Multiplying this fraction by the number of cases will give the expected number of exposed 
cases, needed for the standardization. 
Thus we have estimated both the observed number of exposed cases and the expected 
number of exposed cases. The third and final step is to use these numbers to calculate the 
standardized population attributable risk and RR (Appendix, equations 7 and 8) 
To derive confidence intervals for the population attributable risk, the variance of the 
population attributable risk can be estimated as shown in the Appendix (equations 9-11). 
Another option would be to apply bootstrapping procedures. Furthermore, when either the 
fraction of female donors or the contributions of each stratum to the population attributable 
risk are reasonably homogeneous across strata, the normal non-weighted average of the 
fraction of female donors can be used directly, without the need to calculate a weighted 
average. Homogeneity of the contributions to the population attributable risk across strata is 
also referred to as absence of effect modification. Effect modification and its impact on the 
choice of method to use for correction will be considered in more detail in the discussion. 
Consider again the example of 20 TRALI patients, each receiving three transfusions, 
while the fraction of blood products donated by female donors is 0.35. From all 60 involved 
donors 24 are again female, but we now assume these are randomly distributed across all 
patients. Therefore, four patients have received only transfusions from male donors, nine 
have received a single transfusion from a female donor, six have received two transfusions 
from female donors and a single TRALI patient has received all three transfusions from 
female donors. Since most patients have received transfusions from both female and male 
donors, it is impossible to tell which of these TRALI cases was caused by male or female 
donors. However, we can estimate that in 10 of our 20 TRALI cases the causal donor must 
have been female (Appendix, equation 5: 4x[0-3x0.35+0.35]+9x[1-3x0.35+0.35]+6x[2-
3x0.35+0.35]+1x[1-3x0.35+0.35]). Note, though, that in 7 of these 10 cases, although the 
causal donor was female, the sex of the donor was a coincidence and the TRALI was not 
caused by a women specific mechanism. Since the fraction of blood products donated by 
female donors was constant for all cases the average (weighted or non-weighted) also 
equals 0.35. The population attributable risk is thus 23% (i.e. [10-20x0.35]/[20-20x0.35]) 
and the RR is 1.9 (i.e. [0.23/[0.77x0.35]]+1). 
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4. Correction by maximum likelihood estimation 
The fourth method involves the use of a statistical model and maximum likelihood methods 
to correct for the number of transfusions received by each TRALI patient. The only data 
needed for this model is the sex of all the donors involved in each TRALI patient. 
In this model there are two unknown parameters, which are estimated simultaneously. 
Firstly, the fraction of female donors in the reference population. Since this fraction is 
estimated from the available data on the donors of TRALI patients, this method does not 
require a reference population to be defined. Secondly, the population attributable risk is 
the fraction of TRALI cases preventable by the exclusion of all female donors. 
For a patient with type I TRALI the causal donor is female. The number of female 
donors among the remaining donors of this patient follows a binomial distribution. For a 
patient with type II TRALI, the total number of female donors will follow a binomial 
distribution. The probability that a given TRALI is of type I is the population attributable 
risk (PAR) and the probability that it is of type II is (1-PAR). Together we can use this 
information to compose a likelihood formula for the probability of observing a given 
number of female donors out of a total number of donors for a person for whom the type of 
TRALI is unknown (Appendix, equations 12-15). 
Maximizing this function with respect to the population attributable risk and the 
fraction of female donors in the reference population, yields the maximum likelihood 
estimates for both. Numerical methods are needed to maximize this function; we used the 
function “optim” of the statistical package R.13 The second derivatives of the log-likelihood 
function can be used to estimate the standard errors of the estimated parameters, however in 
this particular case it is easier to calculate profile-likelihood based confidence intervals.14 
Maximum likelihood methods can also be used when the expected fraction of female 
donors is obtained from population data, as was also the assumption for the other three 
methods. In this case the likelihood function has only one unknown parameter (i.e. the 
population attributable risk). 
We consider again the previous example of 20 TRALI patients, each receiving three 
transfusions, while the fraction of blood products donated by female donors is 0.35. From 
all 60 involved donors 24 are again female and again four patients have received only 
transfusions from male donors, nine have received a single transfusion from a female 
donor, six have received two transfusions from female donors and a single TRALI patient 
has received all three transfusions from female donors. When we applied the 
standardization method (previous method), the result was a population attributable risk of 
23%. If we determine the value of the population attributable risk that gives the maximum 
result from the likelihood formula (with a fraction female donations of 0.35) this would be 






We designed a simulation study in which we created 1,000 datasets with 1,000,000 patients 
each. We used the statistical package R to produce these data sets.13 
1,000,000 patients were set to receive a random number of transfusions in the range 
from one to ten, using a uniform distribution. The fraction of donations by female donors in 
the total population of donors was set at 0.35, based on the Dutch donor population. The 
number of female donors amongst the number of received transfusions was subsequently 
drawn from a binomial distribution. 
The overall probability of developing TRALI was set at 1/5,000 transfusions1 and the 
relative risk associated with a transfusion from a female donor was arbitrarily set at 10. 
This implies that the probability of developing TRALI after a transfusion from a male 
donor equals 1/20,750 transfusions ([1/5,000]/[10x0.35+0.65]). The chance of developing 
TRALI after a transfusion from a female donor is consequently 10/20,750 transfusions. The 
true population attributable risk can be obtained using equation 1 and equals 75.90 % (i.e. 
[3.5-0.35]/[3.5+0.65]=3.15/4.15). 
We had two primary effect measures of interest in our study: the fraction of TRALI 
cases preventable by excluding all female donors (population attributable risk, PAR) and 
the relative risk of TRALI after a transfusion from a female donor compared to a 
transfusion from a male donor. We applied all four proposed approaches to all 1,000 data 
sets. For each of the resulting eight different estimates the median and 5th and 95th 
percentiles of the estimates of the 1,000 simulations were determined. The median of 1,000 
estimates gives an impression of the bias of that approach and the interval between the 5th 
and 95th percentiles about the precision. 





In our simulated data sets the true relative risk (RR) was 10 and the true population 
attributable risk (PAR, i.e. the fraction of TRALI cases preventable by the exclusion of 
female donors) was 75.90%. 
 
Crude estimate and stratification by number of transfusions 
Analyzing the simulated data without correction for the number of transfusions resulted in a 
crude RR of 1.3 (5th to 95th percentile: 1.3 to 1.4) and a crude population attributable risk of 
10.87% (9.48% to 12.22%) (table 2). 
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When the RR was calculated within strata of the number of transfusions it decreased 
exponentially with each additional transfusion (figure 2). A conventional method of 
correction for the number of transfusions consists of pooling these stratum specific RR. 
Pooling resulted in an overall RR of 1.5 (1.4 to 1.5) and a population attributable risk of 
13.82% (12.22% to 15.27%) (table 2), which was hardly better than the unadjusted RR and 
population attributable risk. 
 
Relative risk dilution
















Figure 2: Dilution of the relative risk of female donors on TRALI with increasing number of transfusions, 
compared to the true value. The true value is represented by the filled bar. Error bars represent 5th and 95th 




Applying the four suggested methods to the simulated data resulted in good estimates of the 
population attributable risk and the RR (table 2). The main difference between the results 
was the width of the interval between the 5th and 95th percentiles of 1,000 simulations (table 
2). 
A median total of 1,100 TRALI cases (5th to 95th percentile: 1,044 to 1,150) was 
created per simulation. Of these cases a median of 20 cases (13 to 27) were single donor 
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cases and a median of 64 cases (51 to 77) were unisex cases. All single donor cases are 
inevitably also unisex cases. The two restriction based analyses were based on these cases. 
In the standardization and maximum likelihood analyses all cases could be included, 
resulting in more precise estimates of the RR and population attributable risk (table 2). 
In the maximum likelihood analyses it was also possible to estimate the fraction of 
female donations in the reference population simultaneously with the population 
attributable risk. The median of the estimates of this fraction was 0.3496 (5th to 95th 
percentile: 0.3372 to 0.3634), while the true fraction of female donations in the simulated 
data was 0.3500 (0.3497 to 0.3504). Using the true fraction instead of estimating it 
simultaneously with the population attributable risk resulted in a further increase of the 
precision of the estimated population attributable risk, but had no material effect on the bias 
of the population attributable risk (table 2). 
 
 Table 2: Results of 1,000 simulations to compare the performance of the four 
different suggested approaches with the results after conventional correction 
and with the unadjusted result 
 
 Method of analysis RR (p5-p95)* PAR (p5-p95)*  
 True value 10 75.90  
 Unadjusted 1.3 (1.3-1.4) 10.87 (9.48-12.22)  
 Conventional adjustment † 1.5 (1.4-1.5) 13.82 (12.22-15.27)  
 Single donor 10.23 (4.2-41) 75.72 (52.00-91.90)  
 Unisex 10.13 (6.3-18) 76.16 (65.04-85.79)  
 Standardization 10.12 (6.7-17) 76.14 (66.42-85.15)  
 Maximum Likelihood 10.12 (7.5-15) 76.15 (69.32-82.60)  
 ML, p unknown ‡ 10.07 (6.6-16) 76.15 (66.83-84.12)  
 * (p5-p95) represent 5th and 95th percentiles of estimates from 1,000 simulations.  
 † Conventional correction method using stratification according to the number of transfusions and 
subsequent pooling. 
 
 ‡ Maximum likelihood method assuming the fraction of female donations (p) from the reference 
population to be unknown, therefore estimating the population attributable risk and p 
simultaneously. 
 
 RR: Relative risk. PAR: Population attributable risk.  
 




From the crude results obtained without correction it is clear that the problem of multiple 
transfusions can not be ignored when studying donor related risk factors for TRALI. 
Further, it is shown that conventional methods of correction for the number of transfusions 
do not solve the problem. All four proposed methods for dealing with this problem yield 




Conventional methods (like stratifying by the number of transfusions or adding the number 
of transfusions in a regression model) take the weighted average of the relative risks shown 
in figure 2. Therefore, even if only a few patients have received more than one transfusion, 
the relative risk “corrected for the number of transfusions” by conventional methods will 
already be biased. If there are any patients at all who have received more than a single 
transfusion, one of the four proposed methods should always be used. 
 
Restriction methods 
The restriction methods are the most intuitively clear and computationally easy but, by 
definition, put a further restraint on the already limited number of TRALI cases available. 
Single donor cases are not only rare but any TRALI caused by the transfusion of pooled 
products (i.e. in some blood services either platelets, plasma, or both) can not be studied in 
this way. 
Unisex cases occur more often, which likely contributed to the fact that this approach 
has been applied to real data, in a study of internationally gathered unisex cases.(submitted) 
However, for other donor related risk factors (i.e. parity) information is not available for all 
donors. This information has to be gathered specifically for all donors involved in TRALI 
cases to be able to identify cases receiving either all transfusions from parous donors, or all 
transfusions from nulli-parous donors. When known, this information can be used more 
efficiently by applying one of the other methods for correction. 
 
Standardization 
If information on the reference group is available, standardization can be used as a method 
for correction. This method uses the data a bit less efficiently than maximum likelihood 
estimation, but offers the advantage of relatively easy and straightforward calculations. 
Moreover, as with all standardization methods, it is the only valid summary measure in the 
case of effect modification. For instance if the risk associated with female donors of plasma 
rich products is different from the risk associated with female donors of red 
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cells.(submitted) In this case it will provide a summary measure which is the weighted 
average of stratum specific measures, weighted for the actual composition of the total donor 
population which was used for standardization. It is this measure that most accurately tells a 
blood bank which effect to expect from deferral of all female donors. However, it is only a 
valid estimate in the population it was determined in, or a population with very similar 
distribution of female donors across product types and very similar product type usage. In 
contrast, the results of the other three methods are often considered etiologically more 
relevant, since the RR estimated from these methods is less dependent of the population in 
which it was determined. However, since the population attributable risk is always 
dependent on the exposure prevalence in the population it does not share the RR’s 
advantage of greater validity in other populations. The advantage belongs therefore to the 
RR only, while the population attributable risk is likely to be of greater interest to blood 
banks. However, the standardization method also has one drawback, common of all 
standardization methods. The reference population needs to be large enough to avoid 
estimates of the exposure fraction to equal zero or one hundred percent in even a single 
stratum. This is generally not a problem when studying donor related risk factors. 
 
Maximum likelihood estimation 
Maximum likelihood estimation uses the data most efficiently, resulting in the most precise 
estimate of the effect. Another advantage of the maximum likelihood method is that it 
doesn’t necessarily require information on the reference population. The fraction of female 
donors in the reference population and the population attributable risk can be estimated 
simultaneous from information on donors involved in TRALI cases alone. Although 
estimation of two variables does decrease the precision of the estimate, this could be a 
worthwhile tradeoff in some situations. Especially when investigating other donor related 
risk factors, such as leukocyte antibodies. On such risk factors information might already be 
gathered for donors involved in TRALI cases, but could be expensive or cumbersome to 
collect for a large reference group. 
 
Conclusions 
In conclusion, all four methods can be used to study the contribution of donor related risk 
factors to the occurrence of TRALI. The unisex method is reliable and computationally 
easy, but can be difficult to apply to other donor related risk factors. Furthermore, since 
pooling across strata with different relative risks is only allowed with the standardization 
method, this will often be the only method to provide one summary measure. In these 
instances the standardization method provides the most relevant estimate of the effect on 
TRALI incidence that can be expected from implementing new donor deferral policies, 
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Appendix: Mathematical presentation of the four proposed 
methods 
 
Data assumed available or computable 
In standard etiological studies the exposure prevalence among cases is compared with that 
of the source population of the cases in a twofold table (table 1). Appendix table 1 instead 
represents these data for a single patient in a twofold table relating the sex of donors to the 
occurrence of TRALI. In this table a and b represent observed numbers of female and male 
donors and c and d are expected numbers of female and male donors for a patient with an 
equal total number of transfusions. These expected values are estimated from the fractions 
of female and male donations from the relevant donor population and the number of 
transfusions. In fact c and d can also be interpreted directly as expected fractions of female 
and male donors, instead of as expected numbers. For convenience this interpretation will 
be used throughout since it allows for consistent and short notations in all further 
definitions and equations. 
For an analysis with N strata (i.e. N TRALI cases) the stratum specific values for the 
ith stratum (i=1, i=2, ..., i=N) are given by: 
ai = the number of female donors (Appendix table 1). 
bi = the number of male donors (Appendix table 1). 
n1i = the total number of donors (ai+bi; Appendix table 1). 
pi = the fraction of female donors in the reference population. 
From this, the following can be calculated: 
ci = the expected fraction of female donors for a given TRALI patient. 
di = the expected fraction of male donors for a given TRALI patient. 
Furthermore: 
Ai = the (not always directly observed) contribution that this case will make to cell A 
of table 1 of the main paper. 
 
Definition of effect estimator 
Our aim is to estimate the population attributable risk (PAR, the fraction of type I TRALI) 
as a measure of the contribution of female donors to the occurrence of TRALI. It can be 
shown12 in a population with a fraction p of female donors that the PAR equals: 





      (1.) 
With RR the relative risk of developing a TRALI after a transfusion from a female 




 Appendix table 1: Numbers of donors involved in one case of 
TRALI (TRALI +) and reference donors from the relevant 
donor population (TRALI -) according to sex 
 
 TRALI Female donor Male donor Total  
 + a b n1  
 - c d n2  
 Total m1 m2 t  
 All figures represent numbers of donors, but c and d can also be interpreted 
directly as the fractions of female and male donors in the relevant donor 
population. In this case n2, m1, and m2 also loose their interpretation as numbers 
of donors. Since n2, m1, and m2 are not necessary for any of the subsequent 
calculations, this distinction can be ignored. 
Each TRALI patient has his or her own table. For an analysis with N strata (i.e. N 
TRALI cases) the stratum specific values for the ith stratum (i=1, i=2, ..., i=N) are 




Restriction to single donor cases 
In this situation, the RR needed for equation 1 can be directly estimated using a Mantel 

















1        (2.) 
With ai=Ai, bi=Bi, pi=ci and di=1-ci. By estimating p by p = pi/n1i (the average of pi) 
across all strata the population attributable risk of female donors can be calculated by 
completing equation 1. 
 
Restriction to unisex cases 
In this situation, we need to estimate the probability of receiving all transfusions either only 
from male donors or only from female donors. This means we should determine the 
probabilities of receiving transfusions from female or male donors only, given that we 
already know this TRALI patient to be a unisex case. We know pi to the power n1i gives the 
probability of receiving all n1i transfusions from female donors and (1-pi) to the power n1i 
gives the probability of receiving all n1i transfusions from male donors. Adding these 
probabilities gives the probability of being a unisex case (with either male or female 
donors). Dividing either of the previous two probabilities by the probability of being a 
unisex case, gives the probability of receiving all transfusions from female or male donors, 
conditional on being a unisex case: 
Adverse events and multiple transfusions 
67 
































 = 1-ci     (4.) 
Since all donors are of the same sex and only one donor per stratum is considered 
causal Ai and Bi can be estimated by: ai/n1i=Ai and bi/n1i=Bi. 
 
Correction by standardization 
The third method applies direct standardization, according to the exposure in the reference 
population, to correct for the number of transfusions received by each TRALI patient. It 
consists of three steps. First, we estimate A (equation 5): the number of exposed TRALI 
patients in table 1. Second, we calculate the weighted average of pi (p*: equation 6). This is 
the fraction of cases that is expected to be exposed. Multiplying this fraction by the number 
of cases (N1) will give the expected number of exposed cases, needed for the 
standardization. Third, the observed and expected numbers are used to calculate the 
standardized PAR (equation 7) and RR (equation 8). 
Estimation of the number of exposed TRALI patients (A in table 1 of the main paper) 














1      (5.) 
Which equals the sum of all stratum specific contributions to A (Ai). These 
contributions are defined by the observed number of transfusions from female donors (i.e. 
ai) minus the expected number of female donors in all non-causal transfusions. The 
expected number of non-causal transfusions from female donors is rewritten as n1ipi+pi, 
which equals (n1i-1)pi (i.e. the number of non-causal transfusions multiplied by the fraction 
of female donors). Since his method sums the total number of female donors and subtracts 
the number of female donors among non-causal transfusions, it effectively sums the number 
of female donors among causal transfusions (i.e. A in table 1). 
































      (6.) 
The expected fraction of exposed cases (p*) is needed to estimate the observed 
departure from the expected. The weight should therefore reflect the contribution that each 
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stratum makes to this departure. The numerator of the weight (ai-n1ipi) is the actual 
contribution that each stratum makes to the departure from the expected. The denominator 
has two properties. First, by dividing by (1-pi) the weight is corrected for the maximum 
possible departure this stratum could have contributed, give pi. Second, dividing by pi 
corrects for pi itself. This gives a weight proportional to the contribution that this stratum 
would have made to the departure from the expected if everybody in that stratum were 
exposed. In the event of effect modification this standardization procedure is the most 
appropriate because the contribution of the different strata among the exposed remains 
unchanged.16 
The observed and expected measures defined in equations 5 and 6 can be used to 
calculate the PAR. This is done by dividing the deviation of the observed from the expected 










       (7.) 
Where N1 is the total number of TRALI cases. By rearranging equation 1 it can be 
shown that the estimate of the relative risk (RR) defined in terms of the population 
attributable risk (PAR) can be found as: 
RR = ( ) 1*1 +− pPAR
PAR
      (8.) 
To derive confidence intervals for the PAR, the variance of the PAR can be estimated 
by the variance of A, which is the sum of the variances of ai (see below). Another option 
would be to apply bootstrapping procedures. Furthermore, when either pi or the 
contributions of each stratum to the PAR are reasonably homogeneous across strata, the 
normal non-weighted average of pi can be entered directly into equations 7 and 8, without 
the need to calculate p*. 
 
Variance estimation for the PAR 






















































  (9.) 
The variance of ai (i.e. Var(ai) ) depends on the probability that the ith case is a type I 
TRALI, which is given by: 
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1      (10.) 
This probability can be used to calculate the weighted sum of the variance of ai in the 
case of a type I TRALI (variance of a binomial(n1i-1, pi) distribution) and the variance of ai 
in the case of a type II TRALI (variance of a binomial(n1i, pi) distribution). Weighting these 
variances according to the probability given in equation 10 gives the variance of ai: 
Var(ai)  = Iipi(n1i-1)(1-pi) + n1ipi(1-Ii)(1-pi)    (11.) 
 
Correction by maximum likelihood estimation 
In this model there are two unknown parameters, which are estimated simultaneously. 
Firstly, p is the fraction of female donors in the reference population. Secondly, PAR is the 
fraction of TRALI cases preventable by the exclusion of all female donors. 
For a patient with type I TRALI the causal donor is female. The number of female 
donors among the remaining (n1-1) donors follows a binomial distribution. The probability 
that we observe a female donors out of a total of n1 donors is therefore given by: 











    (12.) 
For a patient with type II TRALI, the total number of female donors will follow a 
binomial distribution. The probability that we will observe a female donors out of a total of 










1)1(1      (13.) 
The probability that a given TRALI is of type I is the PAR and the probability that it is 
of type II is (1-PAR). This yields, for a person for whom the type of TRALI is unknown, 
that the probability of observing a female donors out of n1 total donors is: 























1   (14.) 
The likelihood function for the data of all N TRALI cases is given by: 



































1 11 )1()1()1(  (15.) 
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Maximizing this function with respect to PAR and p, yields the maximum likelihood 
estimates for PAR and p. Numerical methods are needed to maximize this function; we 
used the function “optim” of the statistical package R.13 The second derivatives of the log-
likelihood function can be used to estimate the standard errors of the estimated parameters, 
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Although quantitative evidence is lacking, it is generally believed that the majority of cases 
of transfusion-related acute lung injury (TRALI) are caused by female blood donors. We 
aimed to examine the relation between female donors and the occurrence of TRALI. 
 
Study design and methods 
We performed an international, multi-center case-referent study. TRALI patients who were 
diagnosed clinically, independent of serology or donor sex, and had received transfusions 
either only from male donors or only from female donors (Unisex cases) were selected. The 
observed sex distribution among the donors of these TRALI patients was compared to the 
expected sex distribution, based on the relevant donor populations. 
 
Results 
83 clinical TRALI cases were included; 67 cases received only red cells, 13 only plasma 
rich products and 3 both. Among red cell recipients the relative risk of TRALI after a 
transfusion from a female donor was 1.2 (95% confidence interval: 0.69 to 2.1) and among 
plasma rich product recipients the RR was 19 (1.9 to 191). The p-value for the difference 
between red cells and plasma was 0.023. 
 
Conclusion 
Our data support the notion that plasma from female donors is associated with an increased 
risk of TRALI, while red cells from female donors are not.
Chapter 5 
74 




Transfusion-related acute lung injury (TRALI) is currently recognized as the most 
important of the severe side effects of transfusions.1-4 TRALI is characterized by the 
development of acute respiratory distress within six hours after the end of a transfusion, in 
the absence of circulatory overload.5,6 It is clinically indistinguishable from acute 
respiratory distress syndrome (ARDS), but it is rarer and has a better prognosis. The 
estimated incidence is 1:5000 transfusions and the mortality is estimated to be between 5 
and 10%.7-9 Treatment is mostly supportive and in the majority of cases (80%) recovery is 
rapid and complete.7-9 Different etiologies for TRALI have been suggested, but most 
research has been focused on the role of donor leukocyte antibodies,7,10-12 as summarized in 
several recent reviews.13,14 
Leukocyte antibodies are induced by previous exposure to allo-antigens. Such allo-
exposures occur either through pregnancies or through blood transfusions and organ or 
stem cell transplantation. As a consequence leukocyte antibodies are much more prevalent 
in female than in male donors.15-18 Since the UK first started to exclude plasma from female 
donors for transfusion in 2004, several other countries have also implemented or are 
considering to implement this policy to prevent TRALI.1,19,20 Although some encouraging 
data on the effects of such measures have been published,19,21 the evidence does not allow 
quantitative estimation of the effect of excluding plasma from female donors. Furthermore, 
the question arises whether for blood products that contain only small volumes of plasma, 
female donors also confer an increased risk of TRALI.22 
To obtain a quantitative estimate of the contribution of blood products from female 
donors to the occurrence of TRALI is complicated because most TRALI patients have 
received transfusions from female as well as from male donors. However, some TRALI 
patients have received transfusions only from female or only from male donors, which we 
called Unisex cases. The ratio of female to male donors among these Unisex TRALI cases 
can be compared directly to the expected value calculated from the fraction of female 
donors in the respective total donor populations. We set out to quantify the association of 
female donors with the occurrence of TRALI by studying TRALI patients who had 
received transfusions either from female donors only or from male donors only. 
 
Design and Methods 
 
Design and study population 
We performed a case-referent study consisting of TRALI patients who had been diagnosed 
clinically, without knowledge of serology or donor sex. Case-referent study is essentially 
synonymous to case-control study, but it is considered a more appropriate name in some 
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situations.23 In the current study the TRALI case-patients were compared to a reference 
value from the complete donor population, rather than to control-patients without TRALI, 
thus rendering the name case-referent study more appropriate. 
Since TRALI is a rare complication and TRALI patients who have received 
transfusions only from female or only from male donors are inevitably even rarer, no single 
research group or country is likely to be able to collect enough of these cases to perform a 
meaningful study. To overcome this problem we performed an international collaborative 
project. 
We included only TRALI patients defined on clinical criteria alone, because TRALI 
that is defined by serological criteria (i.e. on the basis of presence of antibodies in donor 
blood), has the problem of circularity in reasoning since the diagnosis demands the 
presence of antibodies that are more frequent among female donors.24 We contacted groups 
who had previously published TRALI cases defined on clinical criteria alone, independent 






We asked each contributing group to identify all TRALI patients from their records. From 
all patients previously recorded as TRALI patients we further asked the collaborating 
groups to verify the sex of the donors of all products transfused within six hours before the 
onset of symptoms. Only those patients receiving all transfusions from donors of a single 
sex were eligible for inclusion in the present study. For these patients the presence of the 
other inclusion criteria for this study was checked retrospectively. The selection criteria 
were that the patient had presented with acute dyspnea (as a clinical sign of hypoxemia), 
within six hours after transfusion, without evidence of circulatory overload. For these 
patients, which we call “clinical TRALI” patients, we recorded the number of transfusions, 
the types of transfused products, and the sex of the involved donors. Furthermore, we 
collected data on all criteria of the definition of TRALI according to the Canadian 
consensus conference; these criteria were acute dyspnea, within six hours after transfusion, 
without evidence of circulatory overload, in the presence of new or worsening bilateral lung 
infiltrates in chest X-rays, and the absence of other risk factors for acute lung injury (ALI) 
or acute respiratory distress syndrome (ARDS).5,6 Finally, specifications of blood products 
were recorded and all products containing 250 mL or more of plasma (all plasma and 
platelet products) were classified as plasma rich, while all other products (red cells, always 
leukoreduced and always containing less than 50 mL of plasma) were classified as plasma 
poor. 




Each collaborating group also reported fractions of donations made by female donors as 
registered in their donation databases. For each TRALI patient we documented a unique 
fraction: the fraction of female donors of the specific blood product, in the country or 
region of the reporting group, at the date of occurrence of the TRALI. 
 
Statistical analyses 
Our analysis follows the line of reasoning of one of the methods that we have proposed 
earlier,25 which we briefly and informally recapitulate here. For each TRALI patient we 
first calculated that patient’s individual probability of receiving all transfusions from a 
female donor. This probability was equal to the individually matched fraction of donations 
made by female donors in the relevant donor population, raised to the power of the number 
of these products received by that patient. For example, a TRALI patient receiving three 
units of red cells from a donor population in which 40% of red cells are donated by female 
donors has a probability of receiving all three units from female donors of (0.40)3=0.064. 
For patients who received different product types the probabilities were first calculated for 
the different product types separately and then those probabilities were multiplied. The 
probability of receiving all transfusions from male donors was calculated in the same way 
(in the example (0.60)3=0.216). Adding these two probabilities gives the probability of 
receiving all transfusions from donors of the same sex (in the example 0.064+0.216=0.28), 
which is the probability of being a Unisex case. We then calculated an expected fraction of 
Unisex cases caused by a female donor, by dividing each probability of receiving all 
transfusions from female donors by the probability of being a Unisex case (in the example 
0.064/0.28=0.229). 
 The odds ratio and the corresponding 95% confidence interval (CI) were 
calculated with a matched analysis. The observed value for each individual case (i.e. 1 or 0, 
for all female or all male donors) was matched to the fraction of cases expected to be 
caused by female donors, as calculated for that individual case. In this matched analysis the 
size of the reference group, which was based on national registration data, was relatively so 
much larger than the number of cases (one per stratum) that the contribution of the 
reference group to the variance of the odds ratio was treated as negligible. The odds ratios 
are interpreted as relative risks (RR) throughout. 
To estimate the population attributable risk (PAR) we calculated the average of the 
fractions of female donations from the different donor populations, by weighting for the 
number of TRALI patients contributed by each population. It can be shown25,26 that, for an 
average fraction p of female donors, the PAR equals: 
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Where the RR is estimated by the OR from the matched analysis. The odds ratio and 
its variance (both from the matched analysis) were then used to calculate the population 
attributable risk and the corresponding 95% CI, according to standard formulas.26 
Data were analyzed according to whether the transfused products were red cells or 
“plasma rich” (i.e. either plasma or platelets). Effect modification by product type was 
quantified by calculation of a ratio of relative risks (RRR) and corresponding 95% CI, 
according to standard formulas.27 
All analyses were repeated among the subgroup of patients of whom we had sufficient 
information to assess whether the diagnosis was conform to the Canadian consensus 
criteria5,6: patients who had bilateral infiltrates proven in chest X-rays and who had no other 
risk factors for ALI/ARDS (i.e. excluding “possible TRALI”). In this way we could 
compare the results in all clinical TRALI patients with those patients that had TRALI 





Based on a previous literature study,24 we identified 43 different research groups from 52 
publications, describing clinically defined TRALI patients. All groups for whom email 
addresses could be retrieved were contacted. Apart from the Netherlands, six more groups 
had the relevant data available and were interested in collaborating on this study. Collected 
data pertained to cases occurring between June 1991 and October 2007. 
A total of 83 clinical TRALI patients were included, all presenting with acute dyspnea, 
without evidence of circulatory overload, within six hours after a transfusion. Of these 
patients 67 (81%) had received only red cells, 13 (16%) had received only plasma rich 
products (7 plasma, 6 platelets) and 3 (3.6%) had received both red cells and plasma rich 
products. On average the TRALI patients had received 1.8 transfusions (range 1-8) in the 
six hours preceding the onset of symptoms. 
Of 67 cases caused by a transfusion of red cells 23 had another risk factor for acute 
lung injury, and in 17 no chest X-rays were available (3 patients had both). Therefore, of 
the cases caused by a transfusion of red cells a total of 30 (45%) were classified as TRALI 
patients according to all criteria of the Canadian consensus definition. Of 13 cases caused 
by transfusion of a plasma rich product 2 had another risk factor for acute lung injury, while 
in 1 (8%) a chest X-rays was not available, and the remaining 10 (77%) were classified as 
TRALI patients according to all criteria of the Canadian consensus definition. 























































































































































































































































































































































































































































































































































































































































































The distribution of patients, according to product type and geographical location, with 
numbers of cases associated with male and female donors and corresponding percentage of 
female donors in the reference group are given in Table 1. For both red cells and plasma the 
fraction of products donated by female donors ranged from 0.22 in Poland to 0.51 in 
Finland, while for platelets it ranged from 0.02 in Poland to 0.50 in Spain (Table 1). 
 
Female donors and TRALI risk 
Among 67 red cell recipients the relative risk (RR) of clinical TRALI after a transfusion 
from a female donor was 1.2 (95% CI 0.69 to 2.1) in the matched analysis; among 13 
recipients of plasma rich products (plasma or platelets) the RR was 19 (1.9 to 191) (Table 
2). After restricting the analyses to cases who had proven bilateral infiltrates in chest X-rays 
and no other risk factors for ALI/ARDS (i.e. Canadian consensus definition), the RR for 30 
red cell recipients remained similar at 0.86 (95% CI 0.37 to 2.02) while the RR for 10 
recipients of plasma rich products increased to 66 (1.3 to 3465) (Table 2). 
The ratio of the relative risks of red cell and plasma rich product recipients was 16 (1.5 
to 170), the p-value for the difference in relative risks between these groups was 0.023. 
After limiting to the Canadian consensus definition the ratio became 77 (1.3 to 4410) and 
the p-value for a difference between the groups became 0.046. 
The percentage of cases preventable by the exclusion of female donors (population 
attributable risk, PAR) was 7.0% (-17% to 26%) among red cell recipients, and 86% (17 to 
98%) among recipients of plasma rich products (Table 3). 
 
 Table 2: Relative risk for developing TRALI after a 
transfusion from a female donor 
 
 Product type All cases Canadian consensus*  
 Red cells 1.2 (0.69 to 2.1) 0.86 (0.37to 2.0)  
 Plasma rich 19 (1.9 to 191) 66 (1.3 to 3465)  
 Values are relative risk and (between parentheses) 95% confidence intervals. 
* Only those cases defined completely according to the definition of the 
Canadian consensus conference.5,6 
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 Table 3: Percentage of TRALI cases preventable by the 
exclusion of female donors 
 
 Product type All cases Canadian consensus* 
 Red cells 7.0 (-17 to 26) -5.9 (-45 to 23)  
 Plasma rich 86 (17 to 98) 96 (-126 to 100)  
 Values are percentages of population attributable risk (PAR) and (between 
parentheses) 95% confidence intervals. Negative PAR values can only be 
interpreted as indicative of some protective effect, but not of any size of that 
effect. 
* Only those cases defined completely according to the definition of the 






The risk of TRALI was increased among recipients of plasma rich products from female 
donors, but not among recipients of red cells from female donors. A strong association of 
female donors with the risk of TRALI was expected because, according to the literature, 
most TRALI cases are caused by donor leukocyte antibodies 24 and the prevalence of these 
antibodies in female donors is several times higher than in male donors.15-18 
A unique feature of this study was the restriction to Unisex TRALI cases: patients who 
had received transfusions either only from male or only from female donors. Most patients 
who develop TRALI have received transfusions from several donors of either sex, and the 
one donor causing the TRALI can not be directly identified; therefore the sex of the causal 
donor remains unknown. In our study, since only patients with donors of a single sex were 
included, the sex of the causal donor was known even if the causal donor was not 
identified. Our approach solves the problem of attenuation caused by transfusions from 
multiple donors.25 
Due to the international collaborative effort of this study TRALI patients were selected 
from several different centers or countries with different sized background populations. It is 
therefore not possible to compare the selected patients with the unselected part of the total 
population of TRALI patients, since there is no single identifiable background population. 
However, since all TRALI patients were originally diagnosed independently of donor sex 
and serology this can not have biased our results with respect to donor sex as a risk factor 
for TRALI. The separate effect estimates for red cells and plasma rich products are 
therefore valid in any population, but remain specific for those products. To apply them to a 
different population all that is needed is to know the relative contribution of the different 
product types in that population. 
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The main limitation of this study, pertaining only to the results for plasma rich 
products, is the limited number of cases caused by these products. The selection of Unisex 
cases causes an indirect selection of cases with few transfusions, who in turn will have 
rarely received only transfusions of plasma rich products. Although the distribution of 
product types among the patients in our study may well be different from the background 
population, no bias will be introduced by the selection. Firstly, since we analyzed red cells 
and plasma rich products separately, the fraction of TRALI cases caused by each product 
type in the background population is irrelevant. Secondly, the lesser number of transfusions 
received by TRALI patients in our study, in comparison to other published series, should 
not cause bias either. The mechanism by which TRALI is caused is considered to be an 
immunologic reaction to a single transfusion25 - which is independent of the number and 
type of the other transfusions received by the patient. In spite of the small number of cases 
caused by plasma rich products, a strong association of plasma rich products from female 
donors with an increased risk of TRALI was observed, while no such association was 
observed for red cells. 
The most surprising finding was this lack of association of female donors and the risk 
of developing a TRALI in red cell recipients. To appreciate this finding we considered an 
alternative explanation: if not all included cases were really TRALI patients the effect of 
donor sex would be diluted, obscuring a true association. One source of such misdiagnosis 
could be the patients of whom we did not have all information to be certain that the 
diagnosis was conform to the Canadian Consensus conference. However, the exclusion of 
these patients did not support the notion that the effect was diluted by their inclusion among 
the clinical TRALI patients. In this analysis increasingly stringent selection criteria reduce 
the number of potentially misclassified patients. Misclassified patients would contribute 
donors to the analyses who did not actually cause a TRALI case. These donors would 
therefore follow the sex distribution of the reference group, thus causing the TRALI group 
to become more similar to the reference group. Excluding those patients would therefore 
increase the difference between the TRALI group and the reference group. However, no 
such increase was observed in red cell recipients who, if anything, showed an inverse 
association with female donors after exclusion of clinical TRALI patients who did not 
fulfill all criteria of the consensus definition. Therefore, misclassification of TRALI 
patients does not seem a likely explanation for the lack of association between donor sex 
and the risk of TRALI in red cell recipients. Only for recipients of plasma rich products did 
restriction to consensus definition cases cause an increase in relative risk – which indicates 
that the association might even be stronger. 
Another possible source of misclassification could be transfusion associated 
circulatory overload (TACO). In accordance with the Canadian consensus definition the 
exclusion of TACO was based on the criterion of “no evidence of circulatory overload”, 
which does not specify the type of evidence of which the presence should be excluded. The 
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absence of circulatory overload is therefore mainly based on clinical judgment, which 
makes this criterion the most subjective in the definition. However, to explain our findings 
in red cell recipients almost complete misclassification of these patients would be 
necessary. Even with the subjective nature of this clinical judgment, it seems unlikely that 
nearly all observed TRALI patients related to red cells would be misclassified TACO. This 
is especially unlikely since a strong association with donor sex was observed in recipients 
of plasma rich products, indicating those patients were not misclassified. Furthermore, 
Unisex cases have on average received only few transfusions, which also reduces the risk of 
TACO. 
To compare our findings with what was known from the literature, we performed a 
systematic review of the literature to summarize the direct evidence of the relation between 
female donors and TRALI- see Appendix for methodology and selection criteria. We found 
6 such studies: 4 with a contemporary control group and 2 with a before/after comparison 
(Table 4). 
None of these 6 publications investigated the difference between plasma rich and 
plasma poor products. Publications that make before/after comparisons (i.e. before and after 
introduction of a male-only plasma measure) run the risk of clinical suspicion or reporting 
bias. Only a small portion of TRALI patients are reported, either through lack of clinical 
suspicion/recognition or through poor reporting. The fraction of TRALI patients that is 
reported is inconsistent and highly variable over time and is likely to change strongly after 
well publicized and dramatic measures for the prevention of TRALI (i.e. the exclusion of 
female donors). Therefore, a difference in the number of reported TRALI patients before 
and after implementation of this preventive measure does not necessarily correspond to a 
real difference in the number of TRALI patients. 
Of the 4 publications with a contemporary control group 1 only included six cases and 
1 included only three cases. The remaining 2 did not correct for a difference in the number 
of transfusions (Table 4). TRALI patients have on average received more transfusions than 
other patients which are used as control patients in these studies. Both the chance of 
receiving male-only plasma and the amount of female plasma received depend on the total 
number of transfusions. A higher number of transfusions is strongly related to a higher risk 
of TRALI. Without correction this precludes quantitative conclusions from an observed 
difference in either the prevalence of TRALI between male-only and mixed plasma 
recipients, or a difference in the amount of female plasma received between TRALI 
patients and control patients.24,25 
Considering the limitations of previous studies, their quantitative conclusions are 
uncertain. The methodology which we advocate here and elsewhere,25 is aimed at 
overcoming these potential shortcomings. Furthermore, our study makes a clear distinction 
in the analyses between plasma rich products and red cells and shows a striking difference 
between the associations of female donors with TRALI caused by these products. 
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 Table 4: Six publications investigating the relation 
between female donors and TRALI 
 
 Publication Quantitative interpretation 
limited by 
Description  
 Gajic 2007 36 Difference in number of 
transfusions 
Amount of female plasma 
compared between TRALI 
patients and controls 
 
 Sanchez 2007 37 Statistical power Only six cases (pilot study)  
 Imoto 2007 38 Statistical power Only three cases  
 Wright 2008 19 Before/after comparison Number of reported cases 
before vs. after male-only 
plasma measure 
 
 Chapman 2009 21 Before/after comparison Number of reported cases 
before vs. after male-only 
plasma measure 
 
 Nakazawa 2009 39 Difference in number of 
transfusions 
Risk of TRALI compared 
between male-only and 




Several countries have implemented policies excluding female donors from the donation of 
plasma, to prevent TRALI.1,19,20 Our findings suggest that the vast majority of the TRALI 
cases caused by plasma rich products are indeed preventable by the exclusion of female 
donors. However, to estimate the overall effect on the occurrence of TRALI we also need to 
estimate the relative contribution of plasma rich products to the occurrence of TRALI, 
which can not be estimated directly from our data. The literature gives estimates of the 
contribution of red cells to the occurrence of TRALI varying from one third to more than 
90%.28-32 Based on the literature and our own previously published experience29 we assume 
that on average approximately half of all TRALI cases are caused by transfusion of red 
cells alone. Therefore, exclusion of female donors from donation of plasma rich products 
might prevent roughly half of all TRALI cases. 
In TRALI caused by red cell transfusions our data indicate the role of female donors to 
be negligible. This suggests that current red cell preparation procedures, by reducing the 
amount of plasma in the product, already suffice to effectively reduce the risk posed by 
donor leukocyte antibodies in these products. Therefore, removing the small amount of 
remaining leukocyte antibodies from red cells is likely to have only limited effect. This is in 
agreement with current thinking about the pathogenesis, which suggests that red cells may 
cause TRALI by different mechanisms.30,33-35 




 1.  SHOT. Serious Hazards of Transfusion (SHOT): SHOT Annual Report 2008  2009 [cited 2010 Jan 19] 
Available from http://www.shotuk.org/home.htm. 
 2.  TRIP. "Transfusie Reacties in Patiënten" (TRIP): TRIP rapport 2008  2010 [cited 2010 Jan 19] Available 
from http://www.tripnet.nl/. 
 3.  Engelfriet CP. Haemovigilance. Vox Sang. 2006 Apr;90(3):207-41. 
 4.  Eder AF, Herron R, Strupp A, Dy B, Notari EP, Chambers LA, Dodd RY, Benjamin RJ. Transfusion-
related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma 
from male donors in the American Red Cross. Transfusion. 2007 Apr;47(4):599-607. 
 5.  Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus 
conference: towards an understanding of TRALI. Transfus.Med.Rev. 2005 Jan;19(1):2-31. 
 6.  Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S, Meade M, Morrison D, 
Pinsent T, Robillard P, et al. Toward an understanding of transfusion-related acute lung injury: statement 
of a consensus panel. Transfusion 2004 Dec;44(12):1774-89. 
 7.  Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung 
injury. Transfusion 1985 Nov;25(6):573-7. 
 8.  Moore SB. Transfusion-related acute lung injury (TRALI): clinical presentation, treatment, and prognosis. 
Crit Care Med. 2006 May;34(5 Suppl):S114-S117. 
 9.  Wallis JP. Transfusion-related acute lung injury (TRALI): presentation, epidemiology and treatment. 
Intensive Care Med. 2007 Jun;33 Suppl 1:S12-S16. 
 10.  Bux J. Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox 
Sang. 2005 Jul;89(1):1-10. 
 11.  Dry SM, Bechard KM, Milford EL, Churchill WH, Benjamin RJ. The pathology of transfusion-related 
acute lung injury. Am.J.Clin.Pathol. 1999 Aug;112(2):216-21. 
 12.  Kopko PM. Review: transfusion-related acute lung injury: pathophysiology, laboratory investigation, and 
donor management. Immunohematol. 2004;20(2):103-11. 
 13.  Sachs UJ. Pathophysiology of TRALI: current concepts. Intensive Care Med. 2007 Jun;33 Suppl 1: 
S3-S11. 
 14.  Cherry T, Steciuk M, Reddy VV, Marques MB. Transfusion-related acute lung injury: past, present, and 
future. Am.J.Clin.Pathol. 2008 Feb;129(2):287-97. 
 15.  Boulton-Jones R, Norris A, O'Sullivan A, Comrie A, Forgan M, Rawlinson PS, Clark P. The impact of 
screening a platelet donor panel for human leucocyte antigen antibodies to reduce the risk of transfusion-
related acute lung injury. Transfus.Med. 2003 Jun;13(3):169-70. 
 16.  Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female 
apheresis donors. Transfusion 1999 Jan;39(1):103-6. 
 17.  Payne R. The development and persistence of leukoagglutinins in parous women. Blood. 1962 
Apr;19:411-24. 
 18.  Triulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, Glynn SA, Hillyer CD, Carey P, 
Gottschall JL, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood 
donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion. 2009 
May 18. 
 19.  Wright SE, Snowden CP, Athey SC, Leaver AA, Clarkson JM, Chapman CE, Roberts DR, Wallis JP. 
Acute lung injury after ruptured abdominal aortic aneurysm repair: The effect of excluding donations 
from females from the production of fresh frozen plasma*. Crit Care Med. 2008 May;19. 
 20.  Jutzi ML. Swiss haemovigilance data and implementation of measures for the prevention of transfusion 
associated acute lung injury (TRALI). Transfusion Medicine and Hemotherapy 2008 Apr;35(2):Apr. 
Chapter 5 
86 
 21.  Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, Navarrete C, Lucas G, Soni N, Morgan C, 
et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom 
and the impact of preferential use of male donor plasma. Transfusion. 2008 Oct 28. 
 22.  Win N, Chapman CE, Bowles KM, Green A, Bradley S, Edmondson D, Wallis JP. How much residual 
plasma may cause TRALI? Transfus.Med. 2008 Oct;18(5):276-80. 
 23.  Miettinen OS. Design of Sampling of the Base. In Theoretical Epidemiology, Principles of Occurence 
Research in Medicine. 1 ed. New York: Wiley Medical; 1985. p. 69-83. 
 24.  Middelburg RA, van Stein D, Briet E, van der Bom JG. The role of donor antibodies in the pathogenesis 
of transfusion-related acute lung injury: a systematic review. Transfusion. 2008 Jun 18;48(10):2167-76. 
 25.  Middelburg RA, LeCessie S, Briët E, Vanderbroucke JP, van der Bom JG. A solution to the problem of 
studying blood donor related risk factors when patient have received multiple transfusions. Transfusion 
2010;50(9):1959-66. 
 26.  Rothman KJ, Greenland S. Attributable fraction estimation. In Modern Epidemiology. 2 ed. 1998. 
p. 295-7. 
 27.  Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003 Jan 
25;326(7382):219. 
 28.  Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus.Med.Rev. 
2004 Jul;18(3):184-8. 
 29.  van Stein D, Beckers EA, Sintnicolaas K, Porcelijn L, Danovic F, Wollersheim JA, Brand A, van Rhenen 
DJ. Transfusion-related acute lung injury reports in the Netherlands: an observational study. Transfusion. 
2009 Aug 18. 
 30.  Zupanska B, Uhrynowska M, Michur H, Maslanka K, Zajko M. Transfusion-related acute lung injury and 
leucocyte-reacting antibodies. Vox Sang. 2007 Jul;93(1):70-7. 
 31.  Gajic O, Moore SB. Transfusion-related acute lung injury. Mayo Clin.Proc. 2005 Jun;80(6):766-70. 
 32.  Silliman CC, Boshkov LK, Mehdizadehkashi Z, Elzi DJ, Dickey WO, Podlosky L, Clarke G, Ambruso 
DR. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. 
Blood 2003 Jan 15;101(2):454-62. 
 33.  Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br.J.Haematol. 2007 
Mar;136(6):788-99. 
 34.  Looney MR, Gropper MA, Matthay MA. Transfusion-related acute lung injury: a review. Chest 2004 
Jul;126(1):249-58. 
 35.  Silliman CC, McLaughlin NJ. Transfusion-related acute lung injury. Blood Rev. 2006 May;20(3):139-59. 
 36.  Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, O'byrne MM, Evenson LK, 
Malinchoc M, Degoey SR, et al. Transfusion Related Acute Lung Injury in the Critically Ill: Prospective 
Nested Case-Control Study. Am.J.Respir.Crit Care Med. 2007 Jul 12;. 
 37.  Sanchez R, Bacchetti P, Toy P. Transfusion-related acute lung injury: a case-control pilot study of risk 
factors. Am.J.Clin.Pathol. 2007 Jul;128(1):128-34. 
 38.  Imoto S, Araki N, Shimada E, Saigo K, Nishimura K, Nose Y, Bouike Y, Hashimoto M, Mito H, Okazaki 
H. Comparison of acute non-haemolytic transfusion reactions in female and male patients receiving 
female or male blood components. Transfus.Med. 2007 Dec;17(6):455-65. 
 39.  Nakazawa H, Ohnishi H, Okazaki H, Hashimoto S, Hotta H, Watanabe T, Ohkawa R, Yatomi Y, 
Nakajima K, Iwao Y, et al. Impact of fresh-frozen plasma from male-only donors versus mixed-sex 
donors on postoperative respiratory function in surgical patients: a prospective case-controlled study. 
Transfusion. 2009 Jul 16. 
Female donors and TRALI 
87 
Appendix: Systematic review of the literature 
 
To compare our results with what was known in the literature, we performed a systematic 
review. On December 24 2009 we searched the PubMed database for all publication on 
TRALI and donor sex using the search strategy: ("transfusion related acute lung injury"[All 
Fields] OR TRALI[All Fields]) AND (("female"[MeSH Terms] OR "female"[All Fields]) 
OR ("sex"[All Fields] OR "sex"[MeSH Terms]) OR ("male"[MeSH Terms] OR "male"[All 
Fields]) OR "gender"[All Fields]) AND ("donor"[All Fields] OR “donors”[All fields]). 
We retrieved 125 publications, 100 contained original data, of which 86 had TRALI as 
their primary focus. Of these 86, only 22 actually investigated donor sex as a risk factor, 
while most only mentioned donor sex in relation to antibody testing in a case report or case 
series. Only 4 of the 22 remaining publications included a contemporary control group and 
two made a before/after comparison (Table 4). This left only six publications that actually 
made the comparison we were interested in. The evidence available, from the selected 
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Donor leukocyte antibodies are thought to increase the risk of transfusion-related acute lung 
injury (TRALI). Leukocyte antibodies can be present in blood products from donors who 
have been allo-exposed, mostly through pregnancies. Allo-exposed donors are increasingly 
excluded from donating plasma. Plasma poor products are still donated by allo-exposed 
donors while possible differences between different product types have not been studied. 
We aimed to quantify the contribution of allo-exposed donors to the occurrence of TRALI 
for different blood product types. 
 
Study design and methods 
We performed a case-referent study including all TRALI patients reported by Dutch 
hospitals and all Dutch blood donors. Data on allo-exposure status of donors of all TRALI 
cases reported between January 2004 and October 2008, in the Netherlands, were compared 
to information on the total donor population. 
 
Results 
Allo-exposure status of all 223 involved donors was compared to the expected status. The 
overall percentage of TRALI cases that could have been prevented by the deferral of all 
allo-exposed donors (i.e. population attributable risk; PAR) was 51% (95% confidence 
interval (CI): 14% to 88%). In 19 recipients of exclusively plasma-poor products (mostly 
red cells) allo-exposure of the donors was not associated with TRALI While in 28 
recipients of both plasma-poor and plasma-rich products (>200 mL plasma) the PAR was 
94% (95% CI: 34% to 100%). 
 
Conclusion 
Allo-exposed donors conferred an increased risk of TRALI in recipients of plasma-rich 
products, but not in recipients of plasma-poor products. Although leukocyte antibodies are 
an important risk factor for TRALI, amongst red blood cell recipients another risk factor 
must be more important. 
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Transfusion-related acute lung injury (TRALI) is a clinical syndrome of respiratory distress 
that develops within six hours of transfusion of one or more blood products.1,2 With an 
estimated incidence of 1:5000 transfusions TRALI is one of the most common serious side 
effects of blood transfusions.3 As a form of acute respiratory distress syndrome it has a 
relatively mild prognosis with a mortality commonly estimated to be between 5 and 10% 
and the majority of patients spontaneously recover within 96 hours, without long term 
sequelae.3-5 However, due to the widespread use of blood transfusions, total morbidity and 
mortality associated with TRALI poses a considerable problem.6-8 
Since the publication of the first large case series,3 it has been suggested that TRALI 
can be caused by antibodies directed against either human neutrophil antigens (HNA) or 
human leukocyte antigens (HLA) of both class I and class II.3,9-13 These leukocyte 
antibodies arise from exposure of the immune system to allogeneic cells and tissues (allo-
exposure).14,15 This allo-exposure can occur through pregnancy, transfusion of blood or 
blood components and transplantation of stem cells, tissues or organs. 
As a consequence parous donors and donors who have received blood transfusions are 
more likely to possess leukocyte antibodies.14-19 The prevalence of these antibodies 
increases from below 5% in subjects without known allo-exposure, to 10-15% after blood 
transfusions or a single pregnancy, to well over 30% after three or more pregnancies.14-19 
Allo-exposed donors are therefore considered to be at increased risk of causing TRALI in 
recipients of their blood.20,21 These donors are thought to confer this increased risk 
primarily through the plasma-rich products made from their blood, since these contain the 
highest quantities of antibodies. Therefore plasma from female donors is now excluded 
from use for transfusion in an increasing number of blood services.6,22-25 In some instances 
these measures also include other products considered to be plasma-rich (some types of 
platelet products) and sometimes also male donors with a history of blood transfusion.6,24 
However, the evidence remains largely circumstantial and a quantitative estimation of 
the expected benefit of these measures is therefore not possible. This was also confirmed in 
a recent review of the literature on the contribution of female donors to the occurrence of 
TRALI, which was published in conjunction with an international collaborative case-
referent study on the same subject.26 In the absence of such quantification, these measures 
are based on the precautionary principle. The main obstacle to the quantification of the 
preventable number of TRALI cases is methodological complexity. Most patients have 
received transfusions from more than one donor before developing TRALI. Both ignoring 
this problem and applying conventional methods to correct for the number of transfusions 
result in severely biased effect estimates.27 Therefore, previous estimates of the role of 
donor related risk factors, such as donor sex, parity, transfusion history, and presence of 
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leukocyte antibodies cannot be used to predict the expected benefits of measures directed at 
removing these risk factors from the blood supply. 
Furthermore, the question has now arisen how much leukocyte antibody containing 
plasma is necessary to cause TRALI.28 If the small amount of plasma present in red cells is 
sufficient, this could have the obvious implication of excluding allo-exposed donors from 
all forms of blood donation. On this subject, only anecdotal evidence exist to date and 
further investigation of differences between product types are therefore necessary.28 
We applied new statistical methods, which have been shown to adequately correct for 
the number of transfusions received,27 to quantify the contribution of allo-exposed donors 
to the occurrence of TRALI caused by plasma-poor and plasma-rich products, in all 
reported TRALI cases between January 2004 and October 2008 in the Netherlands. 
 
Design and methods 
 
Study design 
Ethical approval was granted by both the medical ethical committees of the Leiden 
University Medical Center and the Sanquin Blood Bank. 
We performed a case-referent study for which we used the prospectively collected data 
on all TRALI patients reported in the Netherlands from January 2004 till October 2008. For 
each included TRALI patient donors of transfused blood components were identified and 
their allo-exposure status was determined (see below for details). Donors were considered 
allo-exposed if the donor had received one or more blood transfusions, if the donor had 
been pregnant at least one time (including terminated pregnancies), or both. 
Allo-exposure status of donors associated with TRALI patients was compared to the 
allo-exposure status of a reference group of donors (see below for details). These control 
donors donated blood for products that represent the source population of the blood 
components from which the components transfused to TRALI patients were randomly 
drawn. 
The allo-exposure status of the donors of each TRALI patient was matched to the allo-
exposure status that would have been expected, based on the allo-exposure status of the 
reference group (as described below). 
 
TRALI patients: definition, reporting, verification 
TRALI was defined, according to the Canadian consensus definition, as acute respiratory 
distress with new or worsening bilateral infiltrates in the chest radiograph in the absence of 
evidence of circulatory overload, within six hours after completion of a blood transfusion.1,2 
Also in accordance with the consensus definition, a distinction was made between TRALI 
and “possible TRALI”, the latter being clinically diagnosed TRALI in the presence of other 
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risk factors for acute lung injury.1,2 All further mention of TRALI will refer to the complete 
group of all TRALI patients, including “possible TRALI”. When “possible TRALI” is 
excluded, this is stated explicitly. 
Suspected TRALI cases were reported to Sanquin (the national blood supply 
organization in the Netherlands) and TRIP (Transfusion Reactions In Patients, the national 
haemovigilance office in the Netherlands). Reports from hospitals are made by either the 
hospital’s haemovigilance staff or the responsible physicians. 
Reports to Sanquin were verified by physicians of Sanquin’s clinical consultation 
service and reports to TRIP were independently verified by TRIP physicians. Physicians 
from both organizations received additional clinical information from the reporting 
hospitals, as required for verification of the TRALI case. All cases were verified on clinical 
criteria alone, without any knowledge on the donor’s sex or allo-exposure status. Records 
of Sanquin were then compared to those of TRIP for further verification. All confirmed 
TRALI patients were further classified as TRALI without other risk factors for acute lung 
injury or “possible TRALI”. 
 
Donors of TRALI patients: identification, allo-exposure verification 
For each included TRALI patient all blood components transfused within six hours before 
the onset of symptoms were identified by a physician of the reporting hospital. All donors 
of these components were then identified in the database of the national blood supply 
organization in the Netherlands. 
Since allo-exposure variables like parity and transfusion history are not routinely 
collected, we contacted all donors to obtain this information. Donors were sent a 
questionnaire by post, if necessary they received a reminder (with the same questionnaire 
included), and if they did not return the questionnaire they were also contacted by 
telephone. The questionnaire included questions on the donor’s history of transfusions and 
pregnancies. Donors were considered allo-exposed if they reported either one or more 
pregnancies, one or more blood transfusions, or both. 
For donors for whom the allo-exposure status could not be ascertained the average 
allo-exposure status from the other donors of the same TRALI patient was used. There is no 
reason to assume causal donors are more or less likely to have missing information than 
non-causal donors, especially since it is unknown which donors are causal. Therefore, for 
some TRALI patients the missing donor will be causal and for some it will be one of the 
innocent bystander donors. In the first case the total allo-exposure of all donors for that 
patient will be underestimated. In the second case the total allo-exposure of all donors for 
that patient will be overestimated. It can be shown mathematically that, in the applied 





Reference subjects: allo-exposure status 
Male and female donors have different allo-exposure prevalences and the fractions of 
donations from male and female donors changed during the study period. Amongst the 
most important changes was the decision to exclude all plasma from female donors, 
donated after October first 2006, from transfusion. To correct for changes in fractions of 
donations from male and female donors, we first determined these fractions for each year 
and product type separately (as described below; for plasma donated in 2006 we also 
distinguished between donations before October first and donations on or after October 
first). 
We then determined the allo-exposure prevalence for male and female donors 
separately (as described below). Subsequently we calculated the fraction of donations from 
allo-exposed male donors by multiplying the year-of-donation-and-product-type-specific 
fraction of donations by male donors with the fraction of allo-exposure among male donors. 
The fraction of donations from female allo-exposed donors was calculated in the same way 
and these two fractions were added to estimate the total fraction of donations from allo-
exposed donors (i.e. which is also year of donation and product type specific). 
The fraction of products from female donors was determined from complete records of 
all blood donations in the Netherlands. For each product type the national blood supply 
organization records were used to determine the exact numbers produced from donations by 
male and female donors. From these data the fraction of each product type donated by male 
and female donors was calculated, specified by year of donation. This included an average 
of 558,716 whole blood donations per year for red cells and buffy coat derived platelets and 
an average of 51,472 plasmapheresis donations per year for fresh frozen plasma. The 
fraction was matched by donation date rather than transfusion date, to allow for the large 
variations in storage time of fresh frozen quarantine plasma. 
History of blood transfusion and pregnancy were determined as part of the Donor 
InSight study. This study was conducted by Sanquin Blood Bank, between April 2007 and 
April 2009, to gain insight into characteristics and motivation of the Dutch donor 
population. Donors who were not permanently deferred at time of invitation for the Donor 
InSight study were eligible to take part in the study. About 50,000 randomly selected whole 
blood and plasma donors were invited to participate. Each month a random sample of active 
donors was selected from the donor population and invited. Donors received an information 
brochure and questionnaire by regular mail. Donors who agreed to participate in the Donor 
InSight study were asked to return the completed questionnaire by mail. The questionnaire 
also recorded information on blood transfusion and pregnancy history. The Medical Ethical 
Committee Arnhem-Nijmegen in The Netherlands approved the study. 
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The present report is based on data collected from April first 2007 until March 31st 
2008. During this year, a total of 24,179 donors were invited to participate, of which 15,249 
returned the questionnaire and gave informed consent for participation (response 63.1%). A 
random sample of 1,500 donors was drawn from these 15,249 donors who returned the 
questionnaire. Donors were considered allo-exposed if they reported either one or more 
pregnancies, one or more blood transfusions, or both. 
Of the 1,500 randomly drawn donors 279 had not donated blood in the last year and 
were not included in further analyses, since their donation frequency was zero. Amongst the 
remaining 1,221 a further 181 were excluded because their only donation was for safety 
testing purposes (n=10), because they only donated plasma for fractionation purposes 
(n=132), or because based on the donation code they could be identified as specifically 
selected to be non-transfused male donors (n=39). Allo-exposure status among 1,040 
donors was therefore used in the analyses. These 1,040 donors are a random sample of all 
normally donating donors and therefore represent the average allo-exposure status among 
donors donating products transfused to TRALI patients who only received products from 
routine donations. 
Sanquin records were used to link the allo-exposure status of each individual donor to 
the donation frequency of that donor. Numbers of donations from allo-exposed donors were 
calculated by multiplying the numbers of allo-exposed donors by their donation frequency. 
The fractions of products from allo-exposed donors were then calculated for male and 
female donors separately. The average of these male and female specific fractions was 
subsequently calculated, weighted for the fractions of donations from male and female 
donors according to product type and year of donation (determined as described above). 
 
Blood products 
Transfused blood products were classified as either plasma-poor or plasma-rich. Platelet 
concentrates derived from multiple donors were treated as multiple products in all analyses. 
Plasma-poor products were defined as all products containing less than 40 mL plasma. 
This included red cells, the platelets from donors supplying only platelets (i.e. not plasma) 
for a pooled platelet product (i.e. including 4 of every 5 donors for platelets in plasma and 
all donors for platelets in platelet additive solution II (PAS II)). 
Plasma-rich products were defined as all products containing more than 200 mL 
plasma. This included fresh frozen plasma (FFP) and the platelets (and plasma) from the 
donor supplying both platelets and plasma for pooled platelets in plasma. 
 
Plasma measure 
Since October first 2006 all plasma donated for transfusion in the Netherlands is from never 
transfused male donors. In September 2007 the first TRALI patient receiving plasma 
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donated after October first 2006 was reported. Therefore, all TRALI cases occurring since 
September 2007 are considered “post-plasma-measure”. For the primary analyses only 
TRALI cases occurring before September 2007 are included. However, the sub-group of 
patients receiving only plasma-poor products could not have been affected by the plasma 
measure. Therefore, an additional analysis was performed including all TRALI patients 
receiving only plasma-poor products from January 2004 till October 2008. 
 
Statistical analyses 
We aimed to estimate the contribution of allo-exposed donors to the occurrence of TRALI. 
This contribution was expressed as a population attributable risk (PAR; the fraction of 
TRALI cases that could have been prevented by the exclusion of all allo-exposed donors). 
As previously described, standard statistical correction methods are inadequate to 
correct for the number of transfusions received by each TRALI patient.27 We therefore used 
an adapted form of standardization that has been shown in simulation studies to give a valid 
estimate of the contribution of donor related risk factors to the occurrence of TRALI.27 
Briefly, the difference of the observed number of allo-exposed donors of each TRALI 
patient from the expected number for that same TRALI patient was calculated. These 
differences were used to estimate the number of TRALI patients in whom the causal 
transfusion was provided by an allo-exposed donor. The difference of this number from the 
number of TRALI patients expected to be caused by allo-exposed donors was considered 
the excess number of TRALI patients caused by allo-exposure of donors. The maximum 
excess number was the total number of TRALI patients minus the number expected to be 
caused by allo-exposed donors. Dividing the excess number by the maximum excess 
number gives the population attributable risk (PAR; the fraction of TRALI cases that could 
have been prevented by the exclusion of all allo-exposed donors). 
We first performed these analyses for all TRALI patients, giving an estimate of the 
effect of exclusion of all allo-exposed donors from donations of any type. The analyses 
were repeated, selecting patients who had received only plasma-poor product, only plasma-
rich products or mixed product types (both plasma-poor and plasma-rich products). Finally, 
separate analyses were performed for all groups by repeating all analyses after exclusion of 





From January 2004 till September 2007 a total of 50 TRALI cases were reported in the 
Netherlands. Of these, 11 also had other risk factors for acute lung injury and were 
therefore classified as “possible TRALI”. Table 1 shows the numbers of donors and 
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different product types involved separately for all 50 TRALI cases, 39 TRALI cases 
excluding all “possible TRALI”, and in 11 “possible TRALI”. 
From September 2007 till October 2008 another 21 TRALI cases were reported, of 
which 11 (including four “possible TRALI”) received only plasma-poor products. These 11 
patients were included in the additional analysis presented in table 2. All other analyses are 
restricted to the 50 TRALI patients reported before the plasma measure became effective. 
Of 288 donors involved in the total of 61 included TRALI cases data on pregnancy 
and transfusion history could be gathered for 283 (98.3%). 
 
 Table 1: Numbers of TRALI patients, transfusions, and involved 
donors, according to product types 
and classification as TRALI and “possible TRALI” 
 
  TRALI Possible TRALI Total  
 Number of cases 39 11 50*  
 Number of transfusions 179 (4.6/case) 32 (2.9/case) 211  
 Number of donors 223 (5.7/case) 44 (4.0/case) 267  
  Red cells 110 (49%) 23 (52%) 133  
  Platelets† 55 (25%) 15 (34%) 70  
  FFP 58 (26%) 6 (14%) 64  
 * Table 1 represents only TRALI cases occurring prior to September 2007, showing a 
representative composition of the population of TRALI patients before the plasma measure 
became effective. 
 
 † Platelets are mostly pooled concentrates of buffy coat derived platelets from five donors 
in the plasma of one of those donors. Three TRALI cases were reported after receiving 
pooled concentrates of buffy coat derived platelets from five donors in PAS II. The reported 
70 platelet donors represent 14 platelet transfusions: 11 for 10 TRALI cases and 3 for 2 




Allo-exposure in reference subjects 
A final number of 1,040 donors with known allo-exposure status were used to determine 
the expected allo-exposure status of donors involved in TRALI cases. This included 528 
female donors and 512 male donors. Pregnancy was reported by 352 donors and a history 
of blood transfusion by 24. Of these donors 13 reported both previous pregnancies and 
blood transfusions. Of the resulting total of 363 allo-exposed donors 354 (98%) were 
female. Allo-exposed donors constituted 68% of all female donors. 
The average number of donations in 2007 was 2.67 for male donors and 1.84 for 
female donors. Allo-exposure status was not associated with the number of donations. It 





Table 2: Population attributable risk of allo-exposed donors, 
according to product types 
 





risk; allo-exposed donors  
 Overall*  50 267 51% (14% to 88%)  
 Before† 19 38 -10% (-52% to 31%)  
 
Plasma-poor* 
Total† 30 59 -3.5% (-36% to 29%)  
 Plasma-rich*  3 6 24% (-56% to 100%)  
 Mixed*  28 223 94% (34% to 100%)  
 
* Overall: all reported TRALI patients. Plasma-poor: patients receiving only products containing 
less than 40 mL plasma per donor. Plasma-rich: patients receiving only product containing more 




† Before: before the measure; only patients before the plasma measure became effective 
(September 2007), these are from the same period as the other groups (i.e. Overall, Plasma-rich, 
and Mixed). Total: also including 11 patients, receiving plasma-poor products only, who were 
reported between September 2007 and October 2008. 
 
 ‡ Includes all patients until September 2007, except for the third row where, as indicated, patients were included until October 2008.  
 A negative PAR value can only be interpreted as indicative of some protective effect, but not of any size of that effect.  
 
 
Allo-exposed donors and TRALI risk 
The expected percentage of allo-exposed donors among 267 donors, involved in 50 TRALI 
cases was 27%; the observed percentage was 66%. After exclusion of all “possible TRALI” 
among the remaining 223 donors, involved in 39 cases, the expected percentage was 27% 
and the observed was 65%. 
Table 2 represents the percentage of cases preventable by the deferral of allo-exposed 
donors (population attributable risk; PAR). The overall PAR of receiving a transfusion from 
an allo-exposed donor was 51% (95% confidence interval: 14% to 88%). There were only 
three patients who had received exclusively plasma-rich products. For patients who had 
received both plasma-rich and plasma-poor products the PAR of receiving a transfusion 
from an allo-exposed donor was 94% (34% to 100%) (table 2). In 19 patients who had 
received only plasma-poor products (mostly red cells) allo-exposure of the donors was not 
associated with TRALI. 
 
Exclusion of “possible TRALI” cases 
The findings were similar after exclusion of “possible TRALI” cases (figure 1): The PAR 
for the total group was 60% (17% to 100%). For plasma-poor product recipients the PAR 
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was -28% (-86% to 30%). For recipients of both plasma-rich and plasma-poor products the 
PAR was 100% (44% to 100%). 
 






















Figure 1: Population attributable risk of allo-exposed donors for all 50 TRALI patients and for 39 TRALI 
patients, excluding all “possible TRALI". Circles represent the PAR for all 50 TRALI patients and squares 
represent the PAR for 39 TRALI patients after excluding all cases of “possible TRALI”. “Overall” indicates the 
estimate for all patients, regardless of product mix. “Plasma-poor” indicated the estimate for patients receiving 
only plasma-poor products (<40 mL plasma per donor). “Mixed” indicated the estimate for patients receiving both 
plasma-poor and plasma-rich products (i.e. excluding patients receiving either only plasma-poor or only plasma-
rich, as opposed to “Overall” which includes both these groups and “Mixed”.) Bars represent 95% confidence 
intervals. The dashed line indicates the level of null-effect. A negative PAR value can only be interpreted as 





Among recipients of only plasma-poor blood products allo-exposure of donors was not 
associated with an increased risk of TRALI. However, among recipients of both plasma-
rich and plasma-poor blood products allo-exposure of the donors was a major risk factor for 
TRALI. This suggests firstly that allo-exposure of the donor is an important risk factor for 
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TRALI when plasma rich components are transfused, and secondly that the plasma rich 
products are more likely to have caused the TRALI in recipients of both plasma rich and 
plasma poor products. 
We used allo-exposure of the donors as a marker for the increased prevalence of 
leukocyte antibodies. Although only a minority of allo-exposed donors actually develops 
leukocyte antibodies, nearly all leukocyte antibodies are found in allo-exposed donors. We 
assumed there is no other reason, besides leukocyte antibodies, why allo-exposed donors 
can increase the risk of TRALI. It can then be shown that the percentage of TRALI cases 
preventable by the exclusion of allo-exposed donors equals the percentage preventable by 
the exclusion of all donors with leukocyte antibodies. This can be understood since, firstly, 
exclusion of allo-exposed donors also excludes donors with leukocyte antibodies and 
therefore prevents the cases caused by those antibodies. Secondly, it does not prevent any 
other cases than those caused by leukocyte antibodies since allo-exposed donors do not 
cause TRALI through any other mechanism. This is one of the major advantages of using 
the population attributable risk (PAR) as the effect estimate, since it removes the need to 
actually determine the presence or specificity of leukocyte antibodies. 
Beyond the distinction between TRALI and “possible TRALI”, we ignored all other 
data on potential patient risk factors. All diseases can be considered multi-causal and 
TRALI is no exception in this respect.29 However, this was a study of donor related risk 
factors. We consider these risk factors more interesting, since they are relatively easy to 
control, while the patients predisposition for developing TRALI is usually not readily 
influenced. By the analyses in which the allo-exposure status of a patient’s donors was 
matched to the probability of receiving those transfusions from allo-exposed donors, we 
created the statistical equivalent of matching a TRALI patient to an otherwise identical 
patient without TRALI. Therefore, all patient related risk factors become irrelevant (i.e. are 
fully corrected for). 
An assumption necessary for the used analyses to be valid is that the calculated 
probability of receiving a transfusion from an allo-exposed donor should really represent 
this probability at the moment of issuing of the product transfused to the TRALI patient. 
For this to be true the reference group has to be representative for a non-selected, random 
sample of all actively donating donors. We have no reason to assume that in the few years 
of our study the average allo-exposure status of the Dutch female or male changed 
substantially. Furthermore, we corrected for any changes in female to male ratio among 
donations. 
Although we report one of the largest known case series of TRALI patients, a major 
limitation of our study was still the size. The limited size precluded analyses by product 
type and forced us to lump several product types together into plasma-rich and plasma-poor 
products. Even so, we still did not find enough recipients of only plasma-rich products (i.e. 
only three patients) to report an effect estimate for this group. Obviously patients receiving 
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only plasma-rich products are rare and so is TRALI. The combination is therefore even 
rarer and difficult to study. However, since plasma-poor products show no association with 
allo-exposed donors, any association seen in the patients receiving both must be due to 
plasma-rich products. Since the population attributable risk in this group is close to one, it 
is suggested that nearly all the cases in this group are caused by plasma-rich products. 
Further, the population attributable risk for these plasma-rich products must also be close to 
one. This is further supported by the differences between the recipients of plasma-poor 
products and the total group (the latter reflecting the weighted average of all plasma-rich 
products and all plasma-poor products). 
TRALI is known to be underreported and this underreporting may be selective for 
plasma-rich of plasma-poor products. This could influence our conclusion that plasma-rich 
products are more likely to cause TRALI, but none of our other conclusions. Only if 
reporting was selective for the presence of leukocyte antibodies or allo-exposed donors, this 
could cause bias in the conclusions that TRALI after plasma-poor products is not associated 
with allo-exposed donors and that TRALI after plasma-rich products is. However, since this 
information was not available to the reporting physicians, this reporting bias can not be a 
problem in our study. 
Our results indicate that half of all TRALI cases may be preventable by the exclusion 
of all allo-exposed donors, which is in close agreement with a previous estimate of the 
population attributable risk of female donors.26 Furthermore, our findings confirm that allo-
exposure of the donor is the dominant determinant for TRALI in patients receiving plasma-
rich products, while for plasma-poor products other risk factors must be more important. 
This is in agreement with the characteristics of a limited number of TRALI cases reported 
in the 2008 annual SHOT (Serious Hazards Of Transfusion) report.25 Of 17 TRALI cases 
described in this report, 11 involved the transfusion of red cells (six received only red 
cells). In none of the ten completely investigated cases were concordant leukocyte 
antibodies found in donors of the transfused red cells. For all five cases in which leukocyte 
antibodies were identified, the implicated products were either fresh frozen plasma (three 
cases) or platelets (two cases).25 
We also repeated all analyses after exclusion of all “possible TRALI” cases. Some of 
these “possible TRALI” cases were probably not TRALI, but rather acute lung injury 
caused independently of transfusion. Therefore, they should not show any association with 
risk factors for TRALI and cause some dilution of the estimated effect. Consequently, 
excluding these cases can be expected to increase any observed association. Only minor 
increases were observed. The estimate for the total group (overall estimate) reflects a 
weighted average of effects exerted through plasma-poor and plasma-rich product. Changes 
therefore reflect the weighted average of changes in different directions (i.e. simultaneous 
increase of a negative association for plasma-poor products and a positive association for 
plasma-rich products) and can not be interpreted directly. 
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In conclusion, our findings confirm the increased risk of TRALI associated with allo-
exposed donors, which are used as a proxy for leukocyte antibodies. However, this 
association was only observed for plasma-rich products. Allo-exposed donors are almost 
exclusively female and female donors are increasingly being excluded from donation of 
plasma-rich products. Therefore, the contribution of plasma-rich products from allo-
exposed donors to the occurrence of TRALI is dwindling and the relative importance of red 
cell transfusions is steadily growing. 
Already nearly half of the reported TRALI cases in this study were caused by red cells 
alone. At present little is known about risk factors for TRALI related to red cells. With the 
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TRALI is one of the most serious complications of blood transfusion. It can be caused by 
incompatible leukocyte antibodies in transfused plasma. The objective of this study was to 
quantify the reduction of TRALI following introduction of male-only plasma for 
transfusion as a preventive measure, which took effect in 2007. 
 
Study design and methods 
In the Netherlands all cases of TRALI are reported to the national haemovigilance office. 
All reported cases of TRALI from 2002 to November 2009 were considered for inclusion. 
Those meeting the Canadian consensus clinical definition were included and subdivided 
according to whether or not the patient had received quarantine FFP (Q-FFP) in the six-
hour period before the reaction. The numbers of TRALI cases involving plasma donated 
before the measure and of those involving plasma donated after the measure were compared 
to TRALI cases that did not involve Q-FFP in order to adjust for reporting bias. 
 
Results 
110 cases were included in the analysis. Of 68 cases before the measure, 36 involved Q-
FFP. 31 cases occurred after the measure of which 8 involved Q-FFP. Eleven occurred in 
the transitional period, of which 4 involved Q-FFP. The population attributable risk of pre-




In the Netherlands the male-only Q-FFP measure was associated with a 33 percent 
reduction of TRALI cases.
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Transfusion-related acute lung injury (TRALI) is one of the most serious transfusion 
reactions and one of the top three causes of transfusion-related mortality in most 
haemovigilance registries.1,2 According to the Canadian consensus criteria, respiratory 
distress, hypoxia, increased airway resistance and frothy sputum in ventilated patients arise 
within six hours of transfusion and are associated with (new) infiltrates showing on X-ray. 
This is assumed to be due to neutrophils entering the pulmonary interstitium and fluid loss 
into the alveoli.3,4 TRALI has been attributed to incompatibility between donor leukocyte 
antibodies (HLA class I and II antibodies as well as anti-granulocyte antibodies) in 
transfused plasma and recipient leukocytes.5,6 However, in many cases no leukocyte 
incompatibility is found. In the postulated two-hit mechanism of TRALI, a first hit consists 
of neutrophil priming or initial triggering of endothelium in the pulmonary vascular bed. 
The second hit can be the transfusion of leukocyte antibodies incompatible with the 
recipient or other factors that arise during storage of blood products.4 
The proportion of TRALI cases which are deemed to be caused by leukocyte 
incompatibility has been estimated at up to 89%.3 Leukocyte antibodies are mainly induced 
by pregnancy or blood transfusion.7 Therefore several countries where fresh frozen plasma 
(FFP) is used for transfusion have introduced FFP preferentially or exclusively derived 
from male donors who have never received a blood transfusion with the aim to reduce the 
number of TRALI cases. In the UK, analysis of ten years of TRALI registration within 
“SHOT” (Serious Hazards of Transfusion) the national haemovigilance office shows that 
implementation of preferential male-only FFP has led to a near-disappearance of TRALI 
associated with leukocyte incompatibility following plasma transfusion.2 However this may 
be partly a consequence of the SHOT method of assessing “imputability”, the likelihood 
that the clinical picture of TRALI is related to transfusion. SHOT grades imputability of 
TRALI reports higher in the presence of patient-incompatible leukocyte antibodies. The 
international consensus definition for TRALI does not include leukocyte incompatibility as 
a criterion.8,9 
The male-only measure became effective in The Netherlands for all quarantine plasma 
(Q-FFP; henceforth in this article we will refer simply to “plasma”) distributed to hospitals 
since 1st July 2007. The aim of the present study was to quantify the reduction of TRALI 




Design and Methods 
 
Design and study setting 
We performed a cohort study among all patients who had a diagnosis of TRALI in the 
Netherlands from 2002 to 2009 with the aim of comparing the incidence of TRALI before 
and after the male-only plasma measure became effective. In the Netherlands all suspected 
cases of TRALI are reported to TRIP (Transfusion Reactions in Patients), the national 
haemovigilance system which became fully operational in 2003. The reports are submitted 
on a paper or digital reporting form; additional information is requested from hospitals if 
necessary for standardized classification. TRIP also receives information on reported 
TRALI cases from the blood service. Inclusion was terminated on 15th November 2009, 




TRALI case definition 
TRALI cases had to conform to the criteria of the international consensus definition of 
TRALI: a patient was included in the cohort if there were clinical findings of hypoxia with 
bilateral infiltrates on the chest X-ray, starting within 6 hours of the transfusion of a labile 
blood component; circulatory overload had to be excluded as a (more likely) cause.8,9 
Information on the clinical condition of the patient was evaluated for known risk factors for 
acute lung injury or other possible causes of hypoxia with a temporal relationship to the 
respiratory distress. 
All reports were reviewed by a panel of transfusion experts and assessed on clinical 
information without considering results of leukocyte serological investigation, which in 
most cases were not available to the reviewing committee. If the patient had a risk factor for 
acute lung injury (e.g. aspiration, toxic inhalation, lung contusion, near-drowning, 
cardiopulmonary bypass, pneumonia, acute pancreatitis, sepsis) the case was flagged as a 
“possible TRALI” according to the consensus definition.8,9 Cases were excluded if there 
were other more likely causes for the respiratory problems. All blood components received 
by the patient up to 6 hours before onset of respiratory symptoms were recorded. 
 
Transfusional setting and analysis periods 
In the Netherlands plasma for transfusion is prepared from apheresis plasma which is 
released after the donor has been retested for infectious diseases after a minimum of six 
months. From October 2006 all plasma collected for Q-FFP and from July 2007 onwards 
all plasma distributed to the hospitals was from male never-transfused donors. Units 
distributed before 1st July 2007 were not recalled from the hospitals and were transfused 
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from the hospital inventory over the following months. Cryosupernatant plasma is 
occasionally used for refractory TTP and prepared on demand from Q-FFP. 
Since 1988 all platelet products and since 2002 all red cell components have been 
leukoreduced by prestorage filtration (<1x 106 leukocytes per unit). Plasma for transfusion 
meets the same specification. Red blood cell concentrates are stored in SAGM additive 
solution and contain less than 20 ml of residual donor plasma. Over 90% of platelet 
concentrates are prepared from five pooled buffy coats and resuspended in either 200 ml of 
plasma from one of the donors (approx. 70% of total platelet units) or platelet additive 
solution with residual circa 85-100 ml plasma consisting of <20 ml of plasma from each 
buffy coat. Apheresis platelets are collected in a volume of 150 to 400 ml donor plasma and 
are used for special indications such as HLA-matched platelets, Parvo B19 or CMV-safe 
products. During the study years the total number of blood components distributed to the 
hospitals annually was approximately 700,000 units.  
For TRALI cases reported after June 2007 the donation date of transfused plasma was 
checked. Reports where any plasma had been transfused were classified according to the 
donation date of the plasma as occurring with products from before or after the measure. 
TRALI cases involving no plasma were assigned to the same period as any plasma-
associated TRALI in that month. The three analysis periods were: before the measure (2002 
– June 2007), the transitional period during which cases were associated with plasma both 
from before and after the measure (July – November 2007) and after the measure 
(December 2007 – 15 November 2009). Plasma-associated cases during the transitional 
period were assigned according to the date of donation of the plasma and the cases without 




We compared the number of reported TRALI cases from before introduction of the male-
only measure with the number after it had become effective. If the measure was effective a 
reduction will be seen in the number of TRALI patients who received one or more units of 
plasma, with or without other blood components, when only male plasma was available for 
transfusion. The number of reported cases where the patient had not been transfused with 
plasma reflects the overall sensitivity of TRALI detection and reporting in any period. This 
number was used to correct for changes in this sensitivity. 
We expected that after the measure became effective there would be a drop in the 
proportion of TRALI reports after transfusion of plasma against the total number of 
reported TRALI cases. The drop represents the population attributable risk (PAR) for 
female plasma as available prior to the measure, and corresponds to the fraction of TRALI 
prevented by the implementation of male-only plasma. An additional sensitivity analysis 
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was performed, calculating the PAR separately for the ramp-up phase of reporting to TRIP 
(2002 – 2004) and for the plateau phase (2005 – July 2007). The main result was 
recalculated with the omission of reports from the interim period as an additional 
verification. 
The formula used is:  
PAR = (RB – RA)/RB = 1 – risk after/risk before 
with RB the risk of TRALI in transfusion recipients before the measure and RA the risk in 
transfusion recipients after the measure. 
During the reporting period there was little change in numbers of blood components 
distributed in the Netherlands,10 so stable proportions of patients transfused with different 
types and combinations of types of blood component are assumed. The number of TRALIs 
(N) reported in a given period is 
N = XfY 
in which X is the “true” incidence rate of TRALIs (number per year), f is the proportion 
detected and reported and Y the follow-up period (years). 
PAR = 1 – (risk after/risk before) = 1 – XA/XB = 1 - (NA/(YAfA))/(NB/(YBfB)) 
For TRALIs where no plasma was transfused the “true” rate cannot have changed since the 
measure was introduced so 
XB, no plasma = XA, no plasma 
Since we collected TRALIs with and without plasma concurrently we can also assume that 
f at any time is the same for TRALI with and without plasma. This allows the proportion 
YAfA/(YBfB) (for all cases) to be estimated by NA, no plasma/NB, no plasma. Thus the PAR was 
calculated as 
PAR = 1 – ((NA/NB)(NB, no plasma/NA, no plasma)) 
simply using the observed numbers of reported TRALIs. 
A confidence interval for the PAR was calculated using 




Characteristics of the study population 
The study population comprised 110 patients with TRALI approved by expert review as 
complying with the TRALI definition. Figure 1 shows the numbers of all suspected 
TRALIs per year from 2002 to 2009 according to the types of blood component(s) received 
by the patient. 
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Figure 1: Reports of suspected TRALI and associated blood components, 2002-2009. RBC: red blood cells, plts: 
platelets, bc: blood component(s). 
 
 
TRALI before and after the male-only plasma measure 
The earliest TRALI involving one or more plasma units from after the measure occurred in 
July 2007, the last case where one or more plasma units dated from before the measure 
occurred in November 2007. Thirty-one of the TRALI cases were designated as “possible 
TRALI” according to the consensus definition because one or more other risk factors for 
acute lung injury (ALI) were present. 
 
Outcomes and estimation 
The annual number of reports of TRALI rose for all types of blood component between 
2002 and 2007, which can be attributed to increased awareness of TRALI. The initial rise in 
total annual number of reports to the new haemovigilance reporting system had leveled off 
in 2005. A total of 68 cases of TRALI occurred before the male-only plasma measure of 
which 36 involved plasma, with or without other types of blood components. From 
December 2007 there were 31 cases of which 8 involved plasma. Four of the eleven cases 
in the transitional period were associated with plasma, two with plasma donated before the 
measure. Table 1 summarizes the numbers of reports with and without plasma per analysis 
period. The overall PAR was 0.33 (95% CI: 0.09 – 0.51) for all TRALI. After exclusion of 
“possible TRALI” it was 0.37 (95% CI: 0.06 – 0.58). In the sensitivity analysis comparing 
the separate periods of 2002 – 2004 and 2005 – July 2007 to that after the measure the PAR 
was comparable though with a wider confidence interval: PAR 0.41 (95% CI: -0.07 – 0.67); 
and 0.31 (95% CI: -0.02 – 0.54) respectively. 
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15 Nov 2009 
PAR 
1 – ((NA/NB) 
(NB, no plasma/NA, no 
plasma)) 
 
 All TRALI 68 11 31  
  with plasma 36 2 before 
2 after 
8  









48 8 23  
  with plasma 28 2 before 
1 after 
7  




(95% CI: 0.06 – 
0.58)  
 * If cases in the interim period are left out of the calculation the PAR becomes: 1 – ((31/68)(32/23)) = 0.37 






The male-only plasma measure was associated with a 33 percent reduction of TRALI in the 
Netherlands, a reduction totally driven by lower numbers of cases where plasma had been 
transfused in combination with red blood cells and/or platelets. The finding implies that 
against the average number of approximately 20 reports per year before the measure, some 
7 of the previously reported cases annually may have been avoided by the measure. 
Moreover, since the plasma measure can only prevent TRALI caused by plasma, this size 
of effect means that the majority of TRALI cases where plasma had been transfused prior to 
the measure were in fact caused by female plasma. The figures in Table 1 show that TRALI 
cases where plasma had been transfused are in the majority in the period before the measure 
and that this is reversed after the measure. 
We observed a higher attributable risk when cases of “possible TRALI” were 
excluded. In some cases where other risk factors for ALI were present, ALI was probably 
not induced by the transfusion. Inclusion of some such cases leads to dilution and 
underestimation of the effect of the measure. The higher attributable risk after exclusion of 
“possible TRALI” is probably more valid and provides further support that there is a true 
reduction. 
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Strengths and limitations 
The strength of this analysis lies in its inclusion of all reported patients meeting the 
standardized criteria for TRALI in a whole country, with as little as possible interference 
from awareness of the results of leukocyte serology testing. Reporting of such a serious 
complication as TRALI to TRIP and/or the blood service is expected to be nearly complete. 
An important advantage is that we use the number of TRALIs not associated with plasma to 
correct for variability in detection and reporting behavior. The fact that a similar effect is 
found in the sensitivity analyses of the sub-periods supports our use of these cases as a 
comparator. 
A limitation of the study is its observational nature and reliance on spontaneous 
reporting of cases. A recent analysis has shown that bias may operate in the decision 
whether to report a reaction as suspected TRALI.12 If any interpretation bias operated it 
could be expected to favor reports of TRALI associated with FFP and to have most strongly 
influenced TRALIs where FFP was the sole product transfused. However the present 
findings do not support this. Also, since most clinicians in The Netherlands are not aware of 
the plasma measure this reporting preference is unlikely to have changed and therefore 
could not have biased our analyses. 
The overall blood use and the proportions of type of blood component remained 
largely stable over the study period, except for a slight (less than 10%) drop in the number 
of both RBC and plasma units distributed to the hospitals between 2002 and 2004. Thus a 
relative reduction of the use of plasma as compared to cellular blood components has not 
contributed to a lower incidence of TRALI. The assumption of unchanged risk associated 
with RBC and platelet transfusion could also be challenged if female plasma donors 
returned to whole blood donation. In fact however female donors continued to donate 
plasma for fractionation.  
The overall incidence of reported TRALI appears to show a downward trend after the 
year 2007 (figure 1). Analyses by TRIP show that there have been increased reports of 
transfusion-associated circulatory overload and other transfusion reactions, suggesting that 
the diagnosis of TRALI is assigned more critically.1 As explained above the calculated drop 
in TRALI is based on the ratio of TRALI cases where plasma was (one of blood 
components) transfused, to cases without plasma, and would be valid despite a reduced 
trend in the overall level of TRALI detection and reporting. 
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Consistency with prior findings 
A reduction by 33% is slightly higher but in the same order of magnitude as suggested by 
the findings of leukocyte serology as reported recently from our country.13 The reduction is 
comparable to observational pre- and post intervention data on ALI in ruptured abdominal 
aneurysm repair from a single UK center (0.39, 95% CI: 0.16 – 0.90).14 An American study 
of TRALI fatalities in 2003–2005 found that 18 out of 38 probable TRALI fatalities (47%) 
were associated with female antibody-positive fresh frozen plasma and might be avoided by 
limiting transfusion of leukocyte antibody-containing FFP.15 This proportion is again 
similar although the relative contribution of allo-immune TRALI associated with FFP 
would not necessarily be the same among cases with fatal outcome. A recent overview of 
probable TRALI (including nonfatal cases) reported by the American Red Cross describes a 
drop from 30 cases associated with plasma transfusion in 2006 to 10 cases in 2008 after 
implementation of male-predominant plasma for transfusion.16 
In the United Kingdom reports to SHOT of TRALI associated with FFP containing 
patient-incompatible leukocyte-reactive antibodies dropped from 10 in 2003 to none in 
2004–2007 since implementation of preferential use of male plasma. This suggests that, if 
supply of exclusively male plasma is achieved, this measure could prevent most or all 
TRALI caused by plasma. As explained above, SHOT assesses the likelihood that a 
suspected TRALI is indeed transfusion-related partly on the basis of the finding of 
concordant HLA antibodies in the transfused unit(s). The overall rate of reported TRALI 
(assessed as highly likely, probable or possible) before the change in the UK was 1.9 per 
100,000 units, compared with 2.6 per 100,000 in 2005-2006 in our registry. In The 
Netherlands, the expert assessors were blinded to the results of serological investigation 
from 2007 onwards. Prior to that year they were not consistently blind to the results but 
these were not used for the clinical definition of TRALI. The calculated reduction in The 
Netherlands is remarkably similar to the effect in the UK despite the important difference in 
the assessment of cases; this is in line with the hypothesis of TRALI cases being prevented 
by elimination of patient exposure to incompatible leukocyte antibodies in plasma from 
female donors. 
 
Meaning of the study, implications for clinicians and policymakers 
Not in all countries are donors excluded if they have been recipients of transfusion. Plasma 
from male donors who have (ever) been transfused should logically also be excluded, 
although it has been established that pregnancy-related HLA antibodies persist for longer 
than antibodies developed following blood transfusion. In The Netherlands it was possible 
to implement the measures for no significant costs and without serious threat to the blood 
(plasma) supply. We adopted the use of male-only plasma for the plasma added to platelet 
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pools in mid November 2009. A further safety improvement will be obtained if this 
achieves a comparable risk reduction for the platelet concentrates preserved in plasma. 
Some blood services have implemented antibody screening for all female donors, with 
repetition of the screening following pregnancy.17 This should have comparable efficiency 
in preventing TRALI, while resulting in fewer donor deferrals, but is associated with 
increased costs. Other countries (e.g. France, Ireland, Norway, and Finland) use pooled 
solvent-detergent (S/D) virally inactivated plasma and report that TRALI is not seen in 
association with this product. Reduction in non-infectious transfusion complications (both 
TRALI and allergic reactions) was included as an important aspect in a recent review of 
cost-effectiveness aspects of this product.18 
 
Conclusion 
In conclusion, our findings suggest that in the Netherlands the male-only plasma measure 
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Donor leukocyte antibodies have been associated with transfusion-related acute lung injury 
(TRALI) and can be present in allo-exposed donors. Donor deferral policies aiming to 
exclude allo-exposed donors are increasingly implemented world wide. We aimed to assess 
leukocyte antibodies prevalence in different sub-groups of allo-exposed donors in the Dutch 
donor population. 
 
Study design and methods 
Consecutive donors were enrolled during routine whole blood donation. Donors filled out a 
questionnaire on allo-exposure history. Blood samples were tested for HLA (LifeScreen 




6034 consecutive donors (60% male) were included. 2.5% reported a history of blood 
transfusions and 51% (of female donors) reported a history of pregnancy. In never allo-
exposed donors the prevalence of granulocyte reactive antibodies was 2.0% (95% CI: 1.6 to 
2.4%) and for HLA antibodies it was 7.0% (95% CI: 6.3 to 7.8%). In previously pregnant 
donors the prevalence of granulocyte reactive antibodies was increased to 3.0% (95% CI: 
2.0 to 4.0%) and for HLA antibodies it was increased to 33% (95% CI: 30 to 36%). 
Prevalence of leukocyte antibodies of all types depended on transfusion history, number of 
pregnancies, time since last pregnancy, and pregnancy outcome. 
 
Conclusion 
14% of Dutch blood donors are allo-immunized against HLA or granulocyte antigens. 
Deferral of all self-reported allo-exposed donors will decrease this prevalence to 9%. 
Deferral of all female donors and transfused male donors will result in a similar prevalence 
among remaining donors but approximately twice as many deferrals. 
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Transfusion-related acute lung injury (TRALI) is a clinical syndrome of respiratory distress 
that develops within six hours of transfusion of one or more blood products.1-3 It has been 
shown that a substantial part of the TRALI cases are caused by antibodies directed against 
either human neutrophil antigens (HNA) or human leukocyte antigens (HLA) of both 
class I and class II.1,4-9. Therefore, deferral of donors with these antibodies is a logical 
preventive measure to reduce the incidence of TRALI. 
Such deferral policies should naturally be based on adequate data of the relative 
prevalence of leukocyte antibodies in different donor groups. Leukocyte antibodies in the 
donor are caused by exposure to cells and tissues of another human being (allo-exposure). 
This allo-exposure may occur through pregnancy, through transfusion of blood or blood 
products and through transplantation of stem cells, tissues or organs. However, not all allo-
exposure events lead to antibody formation (allo-immunization). The prevalence of allo-
immunization increases with the number of allo-exposure events.10-15 Further, it has been 
reported that the prevalence of leukocyte antibodies tends to decrease with time after last 
allo-exposure.11,13,15 
Therefore, the aim of the current study was to asses the prevalence of all leukocyte 
antibodies in the Dutch voluntary, non-remunerated donor population and in subgroups of 
these blood donors, who received prior blood transfusions, had different numbers of 





From July 2008 till August 2008 consecutive donors were recruited at four different blood 
collection facilities in the North Western part of The Netherlands. Donors were registered 
for whole blood donation in the usual way. During this registration, donors were asked to 
participate in the study. Relevant oral and written information concerning the study was 
provided. After consent, participating donors were asked to fill out a short questionnaire 
about transfusion and pregnancy history. Approval for this study was obtained from the 
ethical advisory board of Sanquin, the Dutch national blood supply organization. 
 
Sample processing and leukocyte antibody testing 
During the routine blood donation, blood from the diversion pouch was collected into a 
standard venous blood vacuum serum collection tube. Serum was stored at -80oC until use. 
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HLA antibody testing 
HLA class I and class II antibody screening and specificity determination was performed by 
means of the LifeScreen Deluxe and the Lifecodes LSAI/II assays (Tepnel, Stamford, CT) 
according to the manufacturer’s instructions. 
Screening for the presence of HLA antibodies was performed as follows: 5 μl of 
microbeads coated with purified HLA class I/class II glycoproteins was incubated with 12,5 
μl of donorserum for 30 minutes. After extensive washing to remove unbound antibodies, 
the beads were incubated for 30 minutes with a phycoerythin conjugated anti-Human IgG 
antibody. Test samples were diluted and analyzed in the LifeMatch® Fluoroanalyzer. The 
signal intensity of each bead was compared to the signal intensity of the negative control 
bead which was included in the analysis to determine positivity or negativity for HLA 
antibodies. A positive result was defined according to the manufacturer’s criteria as one or 
more bead sets positive for all three adjective values (Adj). 
Sera of never allo-exposed donors which were considered positive in the Luminex 
Screen analysis were further analyzed for the specificity of the detected HLA class I and/or 
class II antibodies by means of the Lifecodes LSA I and II. Briefly, 40 μl of beads (each 
conjugated with a different single class I or II HLA glycoprotein) was incubated with 10 μl 
of donorserum for 30 minutes. After extensive washing to remove unbound antibodies, the 
beads were incubated for 30 minutes with a phycoerythin conjugated anti-Human IgG 
antibody. After which the test samples were diluted and analyzed on the LifeMatch® 
Fluoroanalyzer. The signal intensity of each bead was compared to the signal intensity of 
the negative control bead. An HLA specificity was considered positive as defined by the 
manufacturer’s criteria as median fluorescent intensity (MFI) value of the first adjective 
(Adj) equal or higher than 2000 MFI. 
 
Granulocyte reactive antibody testing 
The presence of neutrophil specific antibodies of IgG or IgM class was tested by flow 
cytometry with the Granulocyte indirect Immunofluorescence Test (GIFT), based on the 
method of Verheugt et al.16 with a panel of donor granulocytes typed for HNA-1a, 1b, 1c, 
2a and 3a. The presence of neutrophil specific antibodies was further tested with the 
Granulocyte Agglutination Test (GAT),17 with HNA-3a-positive and HNA-3a-negative 
donor granulocyte suspensions. Lymphocyte-reacting antibodies were examined by the 
Lymphocyte ImmunoFluorescence Test (LIFT) according to Décary et al.18 
Donors were first screened with a panel of two typed granulocyte and lymphocyte 
suspensions in the GIFT and LIFT for the presence of IgG and/or IgM granulocyte reactive 
and HLA antibodies. Sera reacting in the LIFT were incubated with a pool of platelets to 
absorb the HLA class I antibodies before testing them in the GIFT and the GAT. If in the 
GIFT an aspecific granulocyte reactive antibody was detected the serum was also tested 
with an FcRIIIb negative granulocyte suspension. 
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Finally, the detected antibodies were confirmed in the Monoclonal Antibody 
Immobilization of Granulocyte Antigens (MAIGA) assay, as previously described.19 
MoAbs against CD16 (238.7, kindly provided by Dr Brian Curtis, Blood Center of 
Southeastern Wisconsin, USA and 3G8, Medarex, inc, California, USA), CD177 (TAG4 
and MEM166, kindly provided by Dr K.Taniguchi, Hiroshima, Japan and Dr V. Horesji, 
Praha, Czech Republic) and CD18 (IB4, Sanquin, Amsterdam) were used. 
 
Statistical analyses 
Descriptive statistics were used to explore the prevalence of different types of leukocyte 
antibodies in blood donors exposed to different risk factors. All point estimates are reported 
with 95% confidence intervals. The control group consisted of never allo-exposed donors, 
defined as: female donors without a history of either pregnancy or transfusion and male 
donors without a history of transfusion. 
To explore changes in leukocyte antibody prevalence over time since the last 
pregnancy, the prevalence was corrected for the number of pregnancies, using 
standardization. To do this, we first calculated antibody prevalences observed after a certain 
time period since the last pregnancy in strata of women with the same number of 
pregnancies. Each of these observed prevalences at a given time since last pregnancy was 
weighted to calculate the ‘pregnancy corrected’ prevalence. The weights were the 
percentages of women with the same number of pregnancies, in the total group, irrespective 
of time since last pregnancy. Only women with one or more pregnancies were used to 
determine the weights, since women who have never been pregnant have no time since last 
pregnancy. This calculation gives the antibody prevalence that would have been expected if 
women in all categories of time since last pregnancy had the same number of pregnancies 
(i.e. if the number of pregnancies was independent of time since last pregnancy). Variance 
and confidence intervals for the standardized prevalence were calculated according to 
standard formulas.20 
For the analyses of the changes in antibody prevalence in time after the last pregnancy 
a different (oppositely directed) effect was observed for women with one or two 
pregnancies compared to women with three or more pregnancies. Therefore, results for 
both groups are reported separately, with correction for differences in the number of 
pregnancies within those groups as described above. 
Leukocyte antibody prevalence after only life births, only aborted (spontaneous or 
induced) pregnancies, and both life births and aborted pregnancies was corrected for the 
number of pregnancies. The antibody prevalence was standardized by weighting according 
to the percentage of women with a given number of pregnancies in the total group, 
irrespective of pregnancy outcome. Weights were based on women with two or more 
pregnancies, since the group with both life births and aborted pregnancies can contain only 
Chapter 8 
128 
women with two or more pregnancies. This standardization gives the antibody prevalence 
that would have been expected if the number of pregnancies was independent of the 
pregnancy outcomes. Variance and confidence intervals for the standardized prevalence 
were calculated according to standard formulas.20 
All donors were tested for leukocyte antibodies, but self-reported variables had some 
missing values. We assumed missingness to be completely at random and therefore 




Participation of 6034 consecutive eligible blood donors was 100%. Baseline variables of 
these donors are reported in table 1. 
 
 Table 1: Baseline variables of tested donors  
 Variable Categories Number* (%)*  
 Sex Male 3614 (60.7)  
  Female 2341 (39.3)  
 Age (median and IQR†)  48 years (35 – 57)  
 Pregnancies 0 1119 (48.3)  
  1 209 (9.0)  
  2 523 (22.6)  
  3 313 (13.5)  
  4 100 (4.3)  
  >4 55 (2.4)  
 Transfusion history Yes 148 (2.5)  
  No 5719 (96)  
  Unkown 91 (1.5)  
 Leukocyte antibodies None 5165 (85.6)  
  HLA Class I 377 (6.2)  
  HLA Class II 521 (8.6)  
  Any HLA 753 (12.5)  
  Granulocyte reactive 137 (2.3)  
  Any 869 (14.4)  
 Numbers of donors do not add up to 6034 in all categories, due to missing values for some variables. 
All 6034 donors were tested for leukocyte antibodies. However, due to double positivity of some 
donors, only the categories “None” and “Any” add up to a total of 6034. 
* Unless otherwise indicated. 
† IQR: Interquartile range 
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Never allo-exposed donors 
The prevalence of HLA antibodies of any class was 7.0% (95% confidence interval (CI): 
6.3 to 7.8%) among never allo-exposed donors and the prevalence of granulocyte reactive 
antibodies was 2.0% (95% CI: 1.6 to 2.4%) among never allo-exposed donors. Among 
4531 never allo-exposed donors (1092 female, 3432 male, and 7 not reporting their sex) 
318 tested positive for HLA antibodies (74 female, 243 male, and one not reporting his or 
her sex) and 137 tested positive for granulocyte reactive antibodies (64 female and 73 
male). The prevalence of antibodies of all types among never allo-exposed donors is shown 
in table 2, according to the sex of the donors. 
 
 Table 2: Prevalences of different antibodies among never allo-exposed donors 
according to sex 
 
  Male donors Female donors Total  
 Type of antibody Prevalence Prevalence Prevalence  
  n=3432 (95% CI) n=1092 (95% CI) n=4524 (5% CI)  
 HLA Class I 2.3% (1.8 to 2.8) 2.8% (1.9 to 3.8) 2.5% (2.0 to 2.9)  
 HLA Class II 5.2% (4.4 to 5.9) 4.6% (3.3 to 5.8) 5.0% (4.4 to 5.7)  
 Any HLA 7.1% (6.2 to 7.9) 6.8% (5.3 to 8.3) 7.0% (6.3 to 7.8)  
 Granulocyte reactive 1.9% (1.4 to 2.4) 2.4% (1.5 to 3.3) 2.0% (1.6 to 2.4)  
 Any leukocyte 8.8% (7.9 to 9.8) 8.9% (7.2 to 11) 8.8% (8.0 to 9.7)  
 
 
Because of the unexpected high prevalence of HLA antibodies in never allo-exposed 
donors, the specificity of these HLA antibodies was further determined. For 108 of the 111 
never allo-exposed donors who tested positive in the screening for HLA class I antibodies, 
we had enough material left to verify the results in the specificity analyses. In 34 of these 
108 the presence or specificity of HLA class I antibodies could not be confirmed. For all 
but one of the 227 donors who tested positive in the screening for HLA class II antibodies, 
we had enough material left for such verification. Seventy-one of these 226 tested negative 
in the specificity analyses. Of the 318 donors who tested positive for HLA antibodies of 
any class we had enough material left for 315. Ninety-three of these 315 tested negative in 
the specificity analyses (27 female and 66 male). This corresponds to false positive rates in 
the screening test of 0.79% (95% CI: 0.52 to 1.0%) for the presence of HLA class I 
antibodies, 1.6% (95% CI: 1.3 to 2.0) for the presence of HLA class II antibodies, and 2.2% 
(95% CI: 2.8 to 2.6%) for the presence of antibodies against HLA of any class. 
Among never allo-exposed donors this false positive rate applies to 95% of donors (i.e. 
the percentage of truly negative donors) resulting in 2.1% false and 5.0% true positivity in 
this group. Therefore the positive predictive value in this group is 70% (95% CI: 69 to 
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72%). In previously pregnant donors the prevalence of a positive test for HLA antibodies 
increases to 33% and the false positive rate therefore applies to only 69% of the population, 
resulting in 1.5% false and 31% true positivity and a positive predictive value of 95% (95% 
CI: 94 to 97%). 
 















































Figure 1: Prevalence of HLA Class I and II and granulocyte reactive antibodies, according to number of 
pregnancies. A: Prevalences of HLA of any class, B: HLA Class I (squares) and II (circles) separately or C: 
granulocyte reactive antibodies are shown in relation to the number of pregnancies. All prevalences were 




Number of pregnancies 
Figure 1 shows the prevalence for the different antibodies according to the number of 
pregnancies for never transfused female donors, irrespective of pregnancy outcome. The 
prevalence of HLA antibodies increases to 38% (95% CI: 30 to 46%) after three or more 
pregnancies. Of 2215 never transfused female donors for whom the pregnancy history was 
known, 1094 had previously been pregnant (irrespective of number or outcome of 
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pregnancies) and 1121 had never been pregnant. On average previously pregnant, never 
transfused female donors have a prevalence of HLA antibodies of 33% (95% CI: 30 to 
36%). For granulocyte reactive antibodies the prevalence among previously pregnant, never 
transfused female donors was 3.0% (95% CI: 2.0 to 4.0%). 
 
Time since last pregnancy 
Figure 2 shows the prevalence of HLA antibodies at different times after the last pregnancy, 
corrected for the number of pregnancies and stratified according to the number of 
pregnancies. Less than 10 years after the last pregnancy the standardized prevalence of 
HLA antibodies was 35% (95% CI: 29 to 40%). Between 10 and 20 years after the last 
pregnancy the prevalence was 32% (95% CI: 27 to 38%), between 20 and 30 years it was 
34% (28 to 40%), and after more than 30 years it was 29% (95% CI: 23 to 36%). Less than 
10 years after one or two pregnancies the prevalence was 36% (95% CI: 30 to 43%) and 
after more than 30 years this decreased to 22% (95% CI: 14 to 29%). Less than 10 years 
after three or more pregnancies the prevalence was 32% (95% CI: 23 to 40%), and after 
more than 30 years it was 41% (95% CI: 30 to 53%). 
The difference in prevalence between the group with one or two pregnancies and the 
group with three or more pregnancies (both corrected for the number of pregnancies) was -
4.6% (95% CI: -15 to 6.0%) after less than 10 years after the last pregnancy, 6.9% (95% CI: 
-3.8 to 18%) between 10 and 20 years, 20% (95% CI: 7.5 to 32%) between 20 and 30 years, 
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Figure 2: Prevalence of HLA antibodies, according to time since last pregnancy.  A: The prevalence was 
standardized for the number of pregnancies and B: stratified according to the categories of “One or two 
pregnancies” (squares) and “Three or more pregnancies” (circles). Within the strata of “One or two pregnancies” 
and “Three or more pregnancies” the prevalence was further standardized for the number of pregnancies. All 





Aborted pregnancies (either spontaneous or induced) reduced the prevalence of antibody 
formation, compared to life births (figure 3). However, this prevalence reduction was 
absent in women with both life births and aborted pregnancies, even after correction for the 
number of pregnancies. 
The difference between the group with life births only and with aborted pregnancies 
only was 18% (95% CI: 3.9 to 31%) for HLA antibodies of any class and 1.3% (95% CI: -
3.9 to 6.6%) for granulocyte reactive antibodies. The difference between the group with life 
births only and the group with both life births and aborted pregnancies was -8.5% (95% CI: 
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Figure 3: Prevalence of different types of antibodies, 
according to pregnancy outcomes. Prevalences are 
compared for women with only life births (triangles), 
only abortions (spontaneous and induced; squares), and 
both life births and abortions (circles). All prevalences 
were determined among never transfused donors with at 
least two pregnancies and standardized for the total 


























































Figure 4: Risk difference of different types of 
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Blood transfusions 
A positive transfusion history showed a positive association with all types of antibodies 
(figure 4). The strongest association was observed for granulocyte reactive antibodies with 
a risk difference of 3.0% (95% CI: -1.7 to 7.7%) and the weakest for HLA Class II 
antibodies with a risk difference of 0.94% (95% CI: -4.3 to 6.2%). For HLA Class I 
antibodies the risk difference was 1.3% (95% CI: -2.8 to 5.4%) and for HLA of any class it 
was 2.7% (95% CI: -3.8 to 9.2%). The overall risk difference for any kind of leukocyte 








































Figure 5: Specificities of 137 granulocyte reactive antibodies, in 3614 male and 2341 female donors, according to 
sex of the donor. 
 
 
Granulocyte reactive antibodies 
Specificities of granulocyte reactive antibodies are shown in figure 5. The overall 
prevalence was higher in women 2.7% (95% CI: 2.1 to 3.4%) than in men 2.0% (95% CI: 
1.6 to 2.5%), with a risk difference of 0.71% (95% CI: -0.090 to 1.5%). This difference was 
most pronounced for antibodies of which no further specificity could be determined beyond 
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their known specificity for granulocytes. For these antibodies the prevalence in women was 
1.5% (95% CI: 1.0 to 2.0%) and in men 0.86% (95% CI: 0.56 to 1.2%), with a risk 
difference of 0.68% (95% CI: 0.10 to 1.3%). For antibodies with confirmed specificities 
against either HNA or FcRIIIb the prevalence in women was 1.2% (95% CI: 0.81 to 1.5%) 
and in men 1.2% (95% CI: 0.76 to 1.6%), with a risk difference of 0.034% (95% CI: -0.53 
to 0.60%) (see table 3A). 
The overall prevalence was also higher in allo-exposed donors 3.2% (95% CI: 2.2 to 
4.1%) than in never allo-exposed donors 2.0% (95% CI: 1.6 to 2.4%), with a risk difference 
of 1.2% (95% CI: 0.12 to 2.2%). The difference between allo-exposed and never allo-
exposed donors did not vary with the specificity of the antibodies (see table 3B). 
 
   Table 3A: Numbers of 
donors tested positive for 
different specificity 
granulocyte reactive 
antibodies, according to 
donor sex 
 Table 3B: Numbers of 
donors tested positive for 
different specificity 
granulocyte reactive 
antibodies, according to 













 FcRIIIb  7 18 25  5 19 24  
 HNA-1a  11 20 31  7 22 29  
 HNA-1b  3 2 5  3 2 5  
 HNA-2a  2 2 4  2 2 4  
 HNA-3a  5 0 5  5 0 5  
 GAT positive  4 10 14  4 10 14  
 non-specific  32 21 53  15 36 51  
 Total  64 73 137  41 91 132  
 
 
Deferral of all allo-exposed donors 
Deferral of all allo-exposed donors would exclude 1297, or 22% (95% CI: 21 to 23%) of 
5828 donors with known allo-exposure status. Allo-exposure was unknown for 206, or 
3.4% (95% CI: 3.0 to 3.9%) of 6034 donors, leading to a maximal total deferral of 1503, or 
25% (95% CI: 24 to 26%). 
Deferral of all donors who were either allo-exposed or for whom allo-exposure status 
is unknown would lead to the exclusion of 468 antibody positive donors, out of a total of 
869, which corresponds to 54% (95% CI: 51 to 57%). However, since the total donor pool 
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would also be reduced by 25%, the percentage of antibody positive donors would only 
decrease from 14% (95% CI: 14 to 15%) to 8.9% (95% CI: 8.0 to 9.7%). 
 
Deferral of all female or transfused donors 
Deferral of all female donors and all transfused male donors, as is currently the practice for 
the donation of plasma for transfusion in the Netherlands, leads to the exclusion of 65% 
(95% CI: 62 to 68%) of all donors carrying antibodies. However, since 43% (95% CI: 42 to 
44%) of the donor population is deferred, the total donor pool is also reduced. Therefore, 




The prevalence of leukocyte antibodies of any type increases with increasing numbers of 
pregnancies, but the increase levels off after three pregnancies. By comparison, the effect of 
blood transfusions is much smaller. In women with one or two pregnancies the prevalence 
decreases with increasing time since the last pregnancy, but this decrease is very limited. 
Women with only aborted pregnancies also have a lower prevalence of leukocyte 
antibodies, but this prevalence is still substantially higher than in never allo-exposed donors 
and also higher than in transfused donors. 
Blood transfusions and few, aborted, or older pregnancies are associated with less 
leukocyte antibodies than many recent life births, but all pregnancies are an important risk 
factor for leukocyte antibodies and blood transfusions are also associated with a minor 
increase in leukocyte antibody prevalence. Although interesting differences in prevalence 
between different groups of allo-exposed donors are observed, these differences are very 
small. Furthermore, most previously transfused donors are already deferred to decrease the 
risk of prion transmission. Finally, only a relatively limited number of donors could be 
preserved by selectively not deferring their specific subgroup of allo-exposure. Therefore, 
there seems to be little justification to selectively exclude only part of the allo-exposed 
donors, since all types of allo-exposure increase the prevalence of leukocyte antibodies to 
some extend. Provided it poses no serious threat to the continuity of the blood supply, 
questionnaire based deferral measures should therefore be directed at all allo-exposed 
donors. However, it should also be noted that the clinical relevance of the detected 
antibodies has not been confirmed. Therefore, any deferral measure based on the 
(predicted) presence or absence of such antibodies is based on the precautionary principle. 
Consequently these measures should only be considered if they pose no threat to the blood 
supply. 
Alternatively, deferral measures based on testing of donors for leukocyte antibodies 
could be considered. In our population 14% of donors would have to be deferred due to 
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allo-immunization, against 25% deferral in the questionnaire based scenario. Testing based 
deferral would of course also have the added advantage of a total removal of all leukocyte 
antibodies from the blood supply, but the financial cost of such measures should be 
carefully weighted against the practical benefits and the potential risks associated with the 
antibodies remaining after deferral of all allo-exposed donors. 
Although deferral of all allo-exposed donors would remove half of the leukocyte 
antibodies from the blood supply, the prevalence would be reduced by only a third, because 
the donor pool would also be reduced in size by a fourth. By also excluding many allo-
exposed donors without antibodies, the antibodies of never allo-exposed donors become 
relatively more important. Allo-immunization rates were comparable between male and 
female never allo-exposed donors (according to self reported pregnancy and transfusion 
history), indicating no reason to exclude women reporting no previous pregnancies. The 
prevalence of leukocyte antibodies in the remaining donor pool would be comparable to 
selective exclusion of allo-exposed donors only. However, excluding all female donors 
would result in almost twice as much donor deferral. 
The leukocyte antibody prevalence in never allo-exposed donors was higher than 
previously reported for both HLA antibodies11,13-15 and granulocyte reactive antibodies.14 
To rule out non-specific antibodies the specificities of HLA antibodies of never allo-
exposed donors were determined. Verification of the specificities of all granulocyte reactive 
antibodies showed almost half to be non-specific for known granulocyte antigens, but 
confirmed all to be granulocyte reactive. Determination of HLA antibody specificities 
showed the false positive rate to be so low that it could not materially influence our 
conclusions. For the high prevalence of HLA antibodies found in never allo-exposed donors 
another possible explanation could be the presence of antibodies against epitopes on HLA 
molecules that are exposed in the test kit but not on cells that have a natural conformational 
structure. However, it is unlikely that the prevalence of these antibodies would change 
dramatically after pregnancy. Therefore, the prevalence of these clinically irrelevant 
antibodies would be expected to be a constant low percentage which would not influence 
our conclusions. Furthermore, when considering possible donor deferral strategies, use of 
the bead-based assay is preferable due to higher sensitivity and greater ease of use in large 
scale screening. In this light it is also important to note that the possible unnecessary 
deferral of probably less than a percent of donors is likely to be preferable over erroneously 
failing to defer a similar or even larger percentage of donors with potentially dangerous 
antibodies. The same arguments would apply to granulocyte reactive auto-antibodies. If a 
low percentage of detected granulocyte reactive antibodies are indeed auto-antibodies, 
which can be present in the donor without causing any symptoms, this percentage will 
likely not change with allo-exposure and the clinical relevance for TRALI could not be 
excluded. Therefore, further distinguishing granulocyte reactive antibodies into auto-
antibodies and allo-antibodies would not be informative. 
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Due to continuously improving methods for the detection of leukocyte antibodies it is 
impossible to name a single method as a gold standard with which to compare all others. 
Since we used a relatively new and very sensitive assay, for the detection of HLA 
antibodies, the primary concern should be for false positive results. As detailed above, 
using manufacturer recommended cut off values did produce some false positive results. 
However, adapting the cut offs would require specific information about which antibodies 
are considered clinically relevant and which are not. For TRALI, this is at present not 
possible. Therefore, we consider the very low false positive rate preferable to a similar, or 
even higher, false negative rate. 
Several studies have previously investigated the association of pregnancies and blood 
transfusions with the occurrence of leukocyte antibodies.10-15 However, techniques for the 
detection of leukocyte antibodies are continuously improved, leading to increased 
sensitivity. Furthermore, due to changes in composition of blood products, the risk of 
developing leukocyte antibodies after receiving a blood transfusion also changes. Recent 
studies have been done in populations in North America,13,15 where the ethnical 
composition of donor populations is very different from the Western European situation. 
Since the ethnical background is associated with different frequencies of HLA and 
granulocyte antigen genotypes, this could also influence the prevalence of leukocyte 
antibodies. However, the observed leukocyte antibody prevalence after pregnancies was 
comparable to two recent North American studies13,15 and, as might be expected, slightly 
higher than an older study.11 Remarkably the observed prevalence were substantially higher 
than a previous German study.14 Even disregarding the granulocyte reacting antibodies that 
were non-specific for known granulocyte antigens, the difference with this German study is 
still bigger than would be expected by chance variations. Any attempt to explain this 
difference must remain purely speculative. It might well be possible that in the Dutch 
population immigrants from different backgrounds have throughout the centuries 
contributed to a more diverse array of HLA and granulocyte antigen genotypes. This would 
increase the chances of an antigen mismatch between a pregnant woman and her child. This 
can, however, not explain the difference in prevalence in male donors. Which highlights the 
importance of independently screening seemingly similar donor populations, since 
unknown differences between populations can apparently have a substantial influence on 
antibody prevalence. 
The most surprising result was the marked difference, in the change of antibody 
prevalence with time since last pregnancy, between women with one or two and three or 
more pregnancies. The observed decrease in prevalence after one or two pregnancies is in 
accordance with previous studies.11,13,15 However, the increase with time after three or more 
pregnancies has not previously been reported. Since there is no plausible biological 
mechanism that could cause antibody prevalence to really increase several decades after the 
last exposure, it seems likely there has been an additional pregnancy related risk factor for 
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antibodies development in the Netherlands that has been removed between 10 and 20 years 
ago. Donors who had their last pregnancy more than 20 years ago would have been exposed 
to this risk factor, while donors who had their last pregnancy less than 10 years ago would 
not have been exposed. This effect has likely been present in donors with one or two 
pregnancies as well, but due to lower persistence of antibodies after fewer immunizing 
events it is completely counteracted by the natural decrease in antibody prevalence in time. 
We also showed aborted pregnancies to have a lower risk of inducing leukocyte 
antibodies, probably due to reduced exposure to allo-antigens. This risk reduction was not 
observed in women with both life births and aborted pregnancies. This may be due to the 
fact that those women mostly have had more than two pregnancies and would therefore, 
even based on their life births alone, be likely to be in the plateau of high antibody 
prevalence after two or more pregnancies. In most previous studies no distinction was made 
between different pregnancy outcomes (life born, stillborn, miscarriage, abortus 
provocatus).14,15 The type of pregnancy outcome could influence both the degree of 
exposure of the mother to paternal HLA or granulocyte antigens and the extent of tissue 
damage and related inflammation involved in this exposure, which together influence the 
probability of developing antibodies. 
A possible concern regarding the ascertainment of information on the history of blood 
transfusions and pregnancies could be that self-reported histories lack the necessary 
accuracy. This could especially be expected for aborted pregnancies. However, the rate of 
aborted pregnancies compared to the rate of life births as reported in our study 
corresponded well with the national average. Assuming the number of life births to be 
reported reasonably accurately, this suggests that under reporting of aborted pregnancies 
was not a problem in our study. 
In conclusion, 14% of Dutch, non-remunerated, volunteer blood donors has been allo-
immunized against HLA or granulocyte antigens. Amongst self reported never allo-exposed 
donors, the prevalence of leukocyte antibodies is 9%. Consequently, the deferral of all allo-
exposed donors (i.e. 25% of all donors) will remove only half the leukocyte antibodies from 
the blood supply, reducing the prevalence by only a third. Deferral of all female and all 
transfused male donors (i.e. over two fifths of all donors) will result in a similar decrease in 
antibody prevalence. 
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The research presented in this thesis aimed primarily to quantify the contribution of female 
and allo-exposed donors to the occurrence of transfusion-related acute lung injury 
(TRALI). We considered these specifics groups of donors since they have a relatively high 
prevalence of leukocyte antibodies,1-6 which the literature suggests are an important risk 
factor for TRALI.7-16 
Leukocyte reactivity of antibodies is rarely caused by auto-immune disorders or 
naturally occurring antibodies with cross-reactivity against leukocytes. Leukocyte 
antibodies most often occur after allo-exposure and the most common form of allo-
exposure is during pregnancy. Therefore, it can be assumed that the overwhelming majority 
of leukocyte antibodies will be found in female (parous) donors. Further we assume there is 
no other mechanism, of any quantitative importance, by which female donors confer a 
higher risk of TRALI than male donors. It can then be shown that all three population 
attributable risks (PAR), for TRALI caused by leukocyte antibodies, allo-exposed donors, 
and female donors, will be approximately the same. The intuition for this is that excluding 
all female donors will exclude (almost) all donors with leukocyte antibodies and therefore 
prevent all TRALI cases caused by leukocyte antibodies. If, furthermore, (almost) no other 
TRALI cases than those caused by leukocyte antibodies are prevented by the exclusion of 
female donors, exclusion of female donors prevents (approximately) the same TRALI cases 
as exclusion of leukocyte antibodies. 
We therefore started by quantifying the evidence from the literature for the role of 
leukocyte antibodies in the etiology of TRALI. In Chapter 2 we selected published TRALI 
cases that were diagnosed independent of donor sex or serological findings but were fully 
serologically investigated after diagnosis (i.e. including all involved donors). We estimated 
that four fifths of these TRALI cases are caused by leukocyte antibodies. In the absence of 
any major distortion by publication bias we would expect a similar proportion of TRALI 




In a series of Dutch TRALI patients 85% of patients received transfusions of more than one 
donor. Due to the low incidence of TRALI the probability of having two causal transfusions 
is negligibly small. Furthermore, even if two transfusions were both individually capable of 
causing TRALI in a given patient, only the first of the two could really be considered 
causal. If the first transfusion caused a patient to be selected as a case all subsequent 
transfusions become irrelevant, since they can no longer contribute to this selection. It is 
this selection that leads a causative exposure to be overrepresented in cases, compared to 
the reference value obtained from the source population or a valid control group. Therefore, 
once this selection is made, the difference in exposure prevalence between the cases and the 
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reference value is fixed and all other transfusions become irrelevant. As a consequence it 
can be assumed that TRALI is caused by a transfusion from only one of the donors, the 
causal donor. 
As shown in Chapter 4, without identification of this causal donor the crude 
quantitative estimate of the contribution of donor characteristics to the occurrence of 
TRALI will always be an underestimation. One solution to this problem is to select only 
TRALI patients who have either received all transfusions from donors with a certain 
characteristic (e.g. female donors) or who have received all transfusions from donors 
without that characteristic (e.g. male donors). In the case where we compare patients with 
only transfusions from female donors to patients with only transfusions from male donors 
we call these TRALI patients unisex cases (Chapter 5). 
 
Risk factors for TRALI 
 
A first analysis of internationally gathered unisex cases showed less that one fifth to be 
caused by female donors. However, this apparent lack of effect could partly be explained 
by the selection of unisex cases. This selection indirectly also selects for patients who 
received only few transfusions and therefore also for patients who have received red cells, 
rather than other, more plasma rich products (platelets and fresh frozen plasma). Separate 
analyses of patients receiving different product types revealed female donors not to confer 
any increase in risk in recipients of red cells. Conversely, of all TRALI caused by plasma 
rich products at least four fifths were estimated to be preventable by the exclusion of female 
donors. It is therefore suggested that in the previous analyses of published TRALI cases 
there was a publication bias favoring cases caused by plasma rich products. This favoring 
could have occurred either directly, or due to the association of plasma rich products with 
leukocyte antibodies, an association which was likely absent from TRALI caused by 
plasma poor products. 
As expected, similar results as those observed in the unisex analyses were found for 
analyses of the contribution of allo-exposed donors to the occurrence of Dutch TRALI 
cases (Chapter 6). This also confirmed the marked difference between plasma rich and 
plasma poor products. Furthermore, previous findings suggest approximately half of the 
Dutch TRALI cases to be caused by fresh frozen plasma (FFP).17 Therefore, it can be 
estimated that the exclusion of all allo-exposed donors (i.e. all female and transfused male 
donors) from the donation of plasma for transfusion (i.e. the Dutch plasma measure, 
effective as of 1st October 2006) should prevent approximately two fifths of all TRALI 
cases in the Netherlands. 
This estimate was also confirmed by an evaluation of the shift in the relative 
contributions of different product types, to the occurrence of TRALI, after implementation 
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of the plasma measure (Chapter 7). From this comparison it was estimated that nearly half 
the number of TRALI cases occurring before the plasma measure were prevented by 
implementation of the plasma measure. 
 
Effect measures for etiological inferences 
 
All the above estimates are population attributable risks (PAR; i.e. preventable fractions). 
The PAR depends heavily on the exposure prevalence, since at lower exposure prevalence 
fewer cases can be caused by exposure, while the number of exposure independent cases 
remains the same, causing the fraction of cases caused by exposure to be lower. For 
example, after implementation of the plasma measure, the PAR for female donors in 
recipients of FFP must logically become zero. Its dependence on exposure prevalence is 
often considered a shortcoming of the PAR, causing it to be considered inferior to the 
relative risk (RR) as a measure of effect in etiological research. However, the RR is not the 
absolute biological constant it is often erroneously claimed or believed to be either. 
Before the plasma measure approximately half of the reported TRALI cases were 
associated with the transfusion of plasma rich products. However, only one fifth of all 
released blood products can be considered plasma rich. Assuming negligible bias due to 
differential reporting of TRALI for patients receiving different product types, this would 
suggest an estimated RR for TRALI after receiving plasma rich products of about five. 
After the plasma measure, the RR of plasma rich products compared to plasma poor 
products will have changed to unity (i.e. by the prevention of four fifths of TRALI from 
plasma rich products and none of the TRALI from plasma poor products). Thus the RR, 
obviously, is not the more stable effect measure it is often claimed to be. 
So, the RR can also change dramatically in response to changes in prevalence of 
(other) risk factors. Stability of the effect measure can therefore not be an argument for 
favoring the RR over the PAR and we must reconsider the value of both. As in all scientific 
inquiry and comparisons, also in the comparison of effect measures, we must first answer 
the question of what exactly we want to know.18 In etiological research we aim to 
understand the contribution of different risk factors to the occurrence of a particular 
disease. We would like to produce an effect measure that reflects an underlying biological 
truth and which is therefore applicable to any population of human beings at any point in 
history. This, unfortunately, is not possible. As the prevalence of other risk factors changes, 
the number of cases caused by biological interactions between the risk factor under study 
and these other risk factors also changes. Therefore, the best we can hope for is an effect 
measure that will be constant and valid in any population of human beings at any point in 
history, given that the prevalence of all other risk factors that interact biologically with this 
risk factor are comparable to the prevalence in the study population. Within this restriction 
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we would like to estimate how many individuals are sensitive to developing disease if 
exposed, but would not develop disease if unexposed. 
The RR minus one gives this number, as a multiple of the number of cases that would 
occur if there was no exposure at all. The PAR divided by the exposure prevalence also 
gives this number, but as a multiple of the number of cases that actually occurs at the 
present exposure prevalence. The exposure prevalence and the PAR (or the exposure 
prevalence and the RR) can be used to calculate, from the number of cases that would occur 
if there was no exposure, the number of cases that actually occurs at the present exposure 
prevalence (and vice versa). Therefore, given a known exposure prevalence, the RR and the 
PAR contain exactly the same information (which also follows from equation 1 in the 
Appendix of Chapter 4). 
Given that we are interested in the effect of a given risk factor, it does not seem 
unreasonable to assume we would determine the exposure prevalence, probably even before 
starting a study into its association with a disease. It would, after all, be impossible to study 
risk factors with zero prevalence and an incredible waste of effort and resources to study 
those with near zero prevalence. Furthermore, in case control studies the exposure 
prevalence has to be estimated to arrive at any effect measure at all. Therefore, the 
information content of the RR and PAR is identical and can not be an argument for the 
preference for either. This preference should instead be based on ease of interpretation, 
which in turn also partly depends on the ease with which related effect measures can be 
derived. 
Ease of interpretation depends heavily on personal preference and prior experience, 
but the fraction of all disease preventable by removal of exposure seems an extremely 
intuitive effect measure. The number of times the risk of disease increases upon exposure 
is, by comparison, a very abstract measure of effect. The only way to increase the 
comprehensibility of this measure is to supply the baseline risk of the disease as well. The 
RR therefore, seems more suitable for prediction modeling, where the baseline risk of 
disease is combined with the effects of many risk factors to give a predicted risk of disease 
over a given period, given a known exposure. 
 
Estimation of the population attributable risk 
 
A major limitation in the use of the PAR in etiological research has been the difficulty in 
correcting for the influence of confounders, which is much more straightforward for the 
RR. Since a confounder, by definition, changes the baseline risk the PAR can not be 
expected to be constant across strata of a confounder. If the total number of cases changes, 
while the number caused by exposure remains the same, the PAR also changes. Therefore, 
the most commonly used method to arrive at a corrected PAR is to correct the RR and 
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calculate a PAR from the corrected RR.19 This requires an estimate of the exposure 
prevalence among cases. However, in the case of confounding the exposure prevalence 
among cases becomes harder to estimate. Since some strata will contribute more cases due 
to the causal effects of confounders, those strata will be over-represented among cases, 
compared to the source population. These strata by definition also have a different exposure 
prevalence, or there could have been no confounding. Therefore, the actual observed 
exposure prevalence among cases should not be used, but rather the exposure prevalence in 
the source population should be ascertained and used in equation 1 in the Appendix of 
Chapter 4. 
Alternatively, the standardization method described in Chapter 4 can be used to arrive 
at a corrected PAR directly. This method can then also be generalized to use with more than 
one case per stratum (by weighing each stratum for the number of cases) and can also be 
used to correct for a known fraction of non-differential misclassification. In the presented 
case where the method is applied to TRALI, all but one transfusion are non-differentially 
misclassified (i.e. non-causal). This gives a fraction of misclassification of (n-1)/n, which 
cancels out against the number of transfusions and gives each stratum an equal weight of 
one. As shown briefly in Chapter 6, in the application to TRALI, this method is also robust 
against missing data, as long as it is missing randomly with respect to causal and non-
causal transfusions. 
Finally, in the before-after comparison in Chapter 7 the PAR was the most easily 
estimable effect measure. In this case the fraction of TRALI cases that was observed to be 
prevented by the plasma measure only needed to be corrected for the completeness of 
observation. 
 
Prevention of TRALI 
 
In conclusion, it seems that many, compounded methodological problems, concerning 
TRALI research specifically and research of side effect of blood transfusions in general, 
have distorted previous effect estimates of risk factors for TRALI. The principal conclusion 
to be drawn from this thesis is that leukocyte antibodies, and thus allo-exposed donors, can 
only contribute importantly to the occurrence of TRALI caused by plasma rich products. In 
plasma poor products other risk factor must be more important. Although the risk of TRALI 
used to be much lower after transfusion of plasma poor products, the prevention of TRALI 
is currently aimed at TRALI caused by plasma rich products. Therefore, plasma poor 
products are becoming relatively more important. 
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Plasma rich products 
From Chapter 8 we can tell that to prevent leukocyte antibodies from entering the blood 
supply, deferral of all female donors is not strictly necessary. Female donors reporting no 
previous pregnancies have an identical prevalence of leukocyte antibodies as male donors. 
Surprisingly, Chapter 8 also shows that deferral of either all allo-exposed donors or all 
female and transfused male donors will only decrease the fraction of leukocyte antibody 
positive donors from one in seven to one in eleven. This is in sharp contrast with the high 
percentages of TRALI cases estimated to be preventable by the same measures (Chapters 5, 
6, and 7), suggesting the antibodies in never allo-exposed donors to be less likely to cause 
TRALI. As also discussed in Chapter 8, this seeming discrepancy could be due to the fact 
that leukocyte antibodies are largely detected by assays that assess only binding to certain 
specific epitopes. These antibodies could also include antibodies with little functional or 
clinical implication. It seems very well possible that these clinically irrelevant, possibly 
naturally occurring, cross-reactive antibodies form the majority of antibodies detected in 
never allo-exposed donors and a substantial minority of those detected in allo-exposed 
donors. 
The overall most efficient measure to prevent TRALI would then be the deferral of all 
self-reported allo-exposed donors from the donation of plasma for transfusion as FFP or the 
suspension of platelets for transfusion. A similarly effective measure, leading to less donor 
deferral would obviously be the exclusion of only the plasma from those donors with 
clinically relevant antibodies. However, with the current assays we can not distinguish 
clinically relevant from irrelevant antibodies. Deferral of all donors with leukocyte 
antibodies is therefore the safer option, but screening for antibodies is prohibitively 
expensive and labor-intensive. Furthermore, given the results from Chapters 5, 6, and 7 it 
seems unlikely that this would add substantially to the safety of plasma rich blood products 
beyond the improvement already offered by exclusion of plasma from allo-exposed donors. 
 
Plasma poor products 
The prevention of TRALI caused by plasma rich products, by the exclusion of plasma from 
allo-exposed donors, is thought to be near complete. Therefore, the prevention of TRALI 
caused by plasma poor products has become the next highest priority. Since leukocyte 
antibodies seem to contribute little, if anything, to the occurrence of TRALI caused by 
plasma poor products, other risk factors must be more important. In this context biological 
response modifiers (BRM) seem the most likely candidate.20-22 Most of these small-
molecule, inflammatory mediators are known to accumulate in cellular blood products 
during storage.21,22 However, since the introduction of universal leukoreduction substantial 
accumulation of specific inflammatory mediators in packed red cells seems unlikely. Non-
specific stimulation of inflammatory processes by cell debris, however, could still play an 
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important role and cell debris is also likely to accumulate during storage. Furthermore, in 
platelet products, specific inflammatory mediators are still released during storage. 
Therefore, storage time and conditions are suggested to be the next, most likely important, 
and most easily investigated risk factors for TRALI caused by plasma poor products. 
It should also be remembered, though, that any factor in a blood product capable of 
either specifically or non-specifically and either directly or indirectly activating recipient 
neutrophils could cause TRALI. Potential candidates could therefore range from trace 
amounts of chemicals released by blood bags to inflammatory mediators produced by the 
donor before donation. The suggestion to investigate storage time as a potential risk factor 
therefore reflects the expected ease of investigation and high potential for intervention, as 
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Transfusion-related acute lung injury (TRALI) is currently the most common serious side 
effect of blood transfusion. As described in Chapter 1 and shown quantitatively in Chapter 
2, the TRALI literature until December 2007 largely consisted of case reports and case 
series. There was a strong suggestion that TRALI could be caused by donor leukocyte 
antibodies, present primarily in parous female donors and transfused donors, which activate 
recipient neutrophils. In The Netherlands this suggestion led to the exclusion of female 
donors and transfused donors from the donation of plasma for transfusion from 1st October 
2006. In this thesis we aimed to quantitatively estimate the expected effect of the 
implementation of this measure. 
In Chapters 3 and 4 we describe and solve several common methodological problems 
in research of side effects of blood transfusions in general and TRALI in particular. Two of 
the methods proposed in Chapter 4 are then used in Chapters 5 and 6 to study the 
contribution of female donors and allo-exposed donors to the occurrence of TRALI. 
Chapter 7 gives an estimate of the actual effect of the plasma measure in The Netherlands 
on the incidence of TRALI. The results from Chapters 5 through 7, though obtained 
through completely different approaches and partly in different populations, are in close 
agreement. Together these chapters suggest nearly all TRALI caused by plasma rich 
products to be preventable by the deferral of female or allo-exposed donors, while there is 
no such effect on the incidence of TRALI caused by plasma poor products. 
In Chapter 8 we also evaluate the effectiveness of the plasma measure at actually 
keeping leukocyte antibodies out of the blood supply. This effectiveness is then compared 
to other potential donor deferral strategies. It is shown that the deferral of only self-reported 
allo-exposed donors is as effective as deferral of all female and transfused male donors. In 
terms of donor management deferral of allo-exposed donors only would be more efficient, 
but in effectiveness to prevent TRALI there is no difference. 
Finally, in Chapter 9, we discuss these findings and some more general issues 
concerning the use of the population attributable risk, as opposed to the relative risk, and 
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Samenvatting (Dutch summary) 
159 
Transfusiegerelateerde acute longschade (transfusion-related acute lung injury; TRALI) is 
op het moment de meest voorkomende ernstige bijwerking van bloedtransfusies. Zoals 
algemeen beschreven in Hoofdstuk 1 en op kwantitatieve wijze aangetoond in Hoofdstuk 2, 
bestond tot december 2007 de literatuur over TRALI voornamelijk uit beschrijvingen van 
één of meer patiënten, zonder controle groep. Er werd wel gesuggereerd dat TRALI 
voornamelijk veroorzaakt zou worden door leukocyten antistoffen van de bloeddonor die de 
neutrofiele granulocyten van de ontvanger zouden activeren. Deze antistoffen worden 
voornamelijk gevonden in vrouwelijke donoren, die zwanger zijn geweest, maar ook in 
getransfundeerde donoren. In Nederland wordt daarom vanaf 1 oktober 2006 alleen nog 
plasma voor transfusie gedoneerd door mannelijke, nooit getransfundeerde donoren. In dit 
project wilden we kwantificeren welk effect we van deze maatregel kunnen verwachten. 
In Hoofdstuk 3 en 4 beschrijven we een aantal methodologische problemen die veel 
voorkomen in het transfusieonderzoek in het algemeen en het TRALI-onderzoek in het 
bijzonder. In Hoofdstuk 4 stellen we ook verschillende oplossingen voor één van deze 
problemen voor. Twee van deze methoden worden vervolgens in Hoofdstuk 5 en 6 
toegepast om de bijdrage van vrouwelijke donoren en donoren die blootgesteld zijn aan 
allogene antigenen aan het optreden van TRALI te kwantificeren. In Hoofdstuk 7 geven we 
een schatting van het werkelijke effect van de invoering van de plasmamaatregel in 
Nederland. Hoewel Hoofdstukken 5 tot en met 7 heel verschillende methoden en 
gedeeltelijk verschillende populaties gebruiken komen de resultaten goed overeen. Samen 
laten deze hoofdstukken zien dat bijna alle TRALI die veroorzaakt wordt door plasmarijke 
producten voorkomen kan worden door het uitsluiten van vrouwelijke donoren en donoren 
die blootgesteld zijn aan allogene antigenen. Voor TRALI die veroorzaakt wordt door 
plasma-arme producten bestaat dit verband echter niet. 
In Hoofdstuk 8 laten we zien welk deel van de leukocyten antistoffen door de huidige 
plasmamaatregel uit de bloedvoorziening gehouden kan worden. Daarnaast tonen we aan 
dat het uitsluiten van plasma van alleen vrouwelijke donoren die zwanger zijn geweest en 
getransfundeerde donoren net zo effectief is als het uitsluiten van plasma van alle 
vrouwelijke en getransfundeerde donoren. 
Tot slot bespreken we in Hoofdstuk 9 het verband tussen de resultaten uit alle eerdere 
hoofdstukken. In Hoofdstuk 9 bespreken we ook wat algemenere onderwerpen zoals het 
gebruik van een populatie attributief risico in plaats van een relatief risico en correctie van 
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